°Q½×°Ï>ÃĵØÂåÃÄ
ªø´Á«ù¦³¥Ø¼Ð»ù500¤¸¥H¤W
·|­û:¥ý¶i 10000164 µoªí®É¶¡:2014/7/22 ¤W¤È 09:05:58
ÃÒ¥æ©Ò­«¤j°T®§¤½§i

(6446)ÃĵØÃĤ½§i¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡A¤wÀòFDA®Ö­ã¡C

1.¨Æ¹êµo¥Í¤é:103/07/21

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò(­Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î

5.µo¥Í½t¥Ñ:¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç(IND½s¸¹119047)¡A¤wÀòFDA¥¿¦¡³qª¾¥i«ö­pµe¶i¦æ(¥ç§Y¬ü°êFDA®Ö­ã±µ¨ü¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç­pµe)¡C

6. ¦]À³±¹¬I:¶i¦æ¤½§i¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

(1)¥»¤½¥q«e©ó102¦~9¤ë26¤é»P¬ü°êFDA¶i¦æPre-IND meeting¡A·|¤¤FDA©x­û«ØÄ³¥»¤½¥q¥i¿ï¾Ü¶È¥H¦b¼Ú¬w¶i¦æ¤§PROUD-PV trail(§YP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É¸ÕÅç)¼Æ¾Úµ²ªG¡A³w°e¬ü°êFDA¥Ó½ÐÃÄÃÒ¡C

(2)PROUD-PV trail«Y¥»¤½¥q±ÂÅv(Out-Licensing)¹Ù¦ñAOP¤½¥q¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡F¸g»PAOP¤½¥q¨ó°Ó«áij©w¡A¥Ñ¥»¤½¥q©e°UAOP¤½¥q¾á¥ôCROÅU°Ý¡A¨ó§U¬ü°êIND¥Ó½Ð°e¥ó¨Æ©y¡C



¶}ª©·|­û¡u¥ý¶i¡v½Ðºô¤Íµo¨¥µÛ­«©ó²z©Ê°Q½×·sÃĶi«×¡AµL¿×¤£²z©Êªº¥´À£¡A½Ð¦Ü¨ä¥Lª©°Ï¡A¤À¬y¬O¬°¤F¦³§Q§ë¸ê¤H·j´M

·|­û:¥ý¶i10000164µoªí®É¶¡:2022/1/10 ¤W¤È 11:54:38²Ä9974½g¦^À³
§ë¸êªÑ²¼ª±¤F40¦~±q¥¼¬Ý¹L³o»ò³g¡A¦ÛªÎªº¤½¥q¡A¯d¤Uªº¬O¯ä¦W......
·|­û:§d°ê¥°10151930µoªí®É¶¡:2022/1/10 ¤W¤È 10:32:51²Ä9973½g¦^À³
¶ýªº

¨p¶ÒµL¼Æ¦¸

®³§ë¸ê¤Hªº¿ú¶RªÑÁÈ¿ú¤Fµ¹¦Û¤v­û¤u

Á«¿ú¤F´NÂk§ë¸ê¤Hªº

³g°]

·|­û:§d°ê¥°10151930µoªí®É¶¡:2022/1/10 ¤W¤È 09:46:46²Ä9972½g¦^À³
¥ý¶i¤j»¡ªº¨S¿ù

¤µ¦~ªÑªF·|³J¬~·|³õ

¤z¤@¸s½Þ¦b·m­¹

·|­û:¥ý¶i10000164µoªí®É¶¡:2022/1/10 ¤W¤È 09:44:29²Ä9971½g¦^À³

§A¬ÝÃĵØÃĤ½¥q¤º³¡ªº¦æ®|¦h¥i´c¡A¤½¥q©Ò¦³¤W¦Ü¤U³£¬O³g§Qªº¡A¤W¦¸90¤¸¼W¸êªº¸êª÷¦b87¤¸Å@½L¡A·í®É¤½¥qÁÙ¥¼®³¨ìFDAÃÄÃÒ¡A

¤½¥q¤í¯ÊÀç¹B¸êª÷¦V©Ò¦³¤pªÑªF¼W¸ê¡A®¿¥Î¸êª÷¨ÓÅ@½L(Á¿ªº¦nÅ¥)¡AúҹϦۤvªº§Q¡A¤½¥q·í®ÉÁÙ¦b­·«BÄÆ·n¤¤«×¤é¡A®³¨ìÃÄÃÒ

«á»ù¤Wº¦¡A´N»°§Ö§â¤§«e©Ò§C»ù¶R¤Jªº»ù®æµ¹¬ù©Ò¦³­û¤u¡A¦h¥i´c°Ú~¤µ¦~ÃĵØÃĪºªÑªF·|¡A«ØÄ³±z¶}½|³o¨Ç¤½¥q¬£³g§Q¦æ®|

·|­û:¥ý¶i10000164µoªí®É¶¡:2022/1/10 ¤W¤È 09:31:37²Ä9970½g¦^À³
www.businesstoday.com.tw/article/category/80392/post/202201060041?utm_source=LINE&utm_medium=text&utm_campaign=2201061900

....,..................................

§A¬ÝÃĵØÃĤ½¥q¤º³¡ªº¦æ®|¦h¥i´c¡A¤½¥q©Ò¦³¤W¦Ü¤U³£¬O³g§Qªº¡A¤W¦¸90¤¸¼W¸êªº¸êª÷¦b87¤¸Å@½L¡A·í®É¤½¥qÁÙ·|®³¨ìFDAÃÄÃÒ¡A

¤½¥q¤í¯ÊÀç¹B¸êª÷¦V©Ò¦³¤pªÑªF¼W¸ê¡A®¿¥Î¸êª÷¨ÓÅ@½L(Á¿ªº¦nÅ¥)¡AúҹϦۤvªº§Q¡A¤½¥q·í®ÉÁÙ¦b­·«BÄÆ·n¤¤«×¤é¡A®³¨ìÃÄÃÒ

«á»ù¤Wº¦¡A´N»°§Ö§â¤§«e©Ò§C»ù¶R¤Jªº»ù®æµ¹¬ù©Ò¦³­û¤u¡A¦h¥i´c°Ú~¤µ¦~ÃĵØÃĪºªÑªF·|¡A«ØÄ³±z¶}½|³o¨Ç¤½¥q¬£³g§Q¦æ®|

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2022/1/10 ¤W¤È 08:52:29²Ä9969½g¦^À³
¤@¡B¬ü°ê¦³¸É§UªvÀøPVÃÄ«~¸g¶O¥Á¶¡«DÀç§Q²Õ´­p¦³¡G

(¤@)PAN Foundation¡GBESREMI¡BJAKAFIV¡BPEGASYS¡C

(¤G)good days¡GBESREMI¡BJakafi¡C

(¤T)GENENTECH PATIENT FOUNDATION¡GPegasy(peginterferon alfa-2a)¡C

¤G¡B±q¬ÛÃöMPNªÀ¸s°Q½×PAN Foundation¸É§UBesremi±¡§Î¡G

(¤@)PAN Foundation has approved Besremi!

PAN °òª÷·|¤w§å­ã Besremi!

(¤G) Today I learned the PAN Foundation is already up to speed about Besremi and is already awarding big annual grants ($8,000+) to eligible patients to help cover copayments for Besremi¡C

¤µ¤Ñ§Ú¤F¸Ñ¨ì PAN °òª÷·|¤w¸g¥[§Ö³t«×¸É§U Besremi ¡A¨Ã¥B¤w¸g¦V²Å¦X±ø¥óªº±wªÌ´£¨Ñ¤jµ§¦~«×ÃØ´Ú¡]8,000 ¬ü¤¸¥H¤W¡^¡A¥HÀ°§U¤ä¥I Besremi ªº¦@¥IÃB¡C

(¥|)If you get approval from your Medicare Part D plan to cover Besremi then I think

you¡¦d have to call the PAN foundation to cancel your existing grant for Pegasys copayments and apply for a new grant to cover Besremi copayments. If I were in your shoes I¡¦d call PAN next week to inquire about whether it will be possible to do this switch in February.

¦pªG±zÀò±o Medicare D ³¡¤À­p¹ºªº§å­ã¥H²[»\ Besremi¡A¨º»ò§Ú»{¬°±z¥²¶·­P¹q PAN °òª÷·|¨ú®ø±z²{¦³ªº Pegasys ¦@¥IÃBÃØ´Ú¨Ö¥Ó½Ð·sªºÃØ´Ú¥H²[»\ Besremi ¦@¥IÃB¡C¦pªG§Ú³B©ó§Aªº¦ì¸m¡A§Ú·|¦b¤U¶g¥´¹q¸Üµ¹ PAN¡A¸ß°Ý¬O§_¥i¥H¦b 2 ¤ë¥÷¶i¦æ¦¹Âà´«¡C

(¤­)Dr. Mesa is prescribing Besremi. Hoping it is in my UHC Medicare Part D formulary. is saying PAN is writing grants for it now.

Mesa³Õ¤h¥¿¦bµ¹ Besremi ¶}³B¤è¡C§Æ±æ¥¦¦b§Úªº UHC Medicare D ³¡¤À³B¤è¤W¡C¾Ú»¡ PAN ²{¦b¦³¸É§U¤F¡C

¤T¡B¤pµ²¡GPAN Foundation¤Îgood daysµ¥²Õ´¤w±NBesremi¦C¤J¸É§UÃÄ«~²M³æ¡A¬Û«H­ì¥»¦bPAN ¥Ó½Ð¸É§U¨Ï¥ÎJAKAFIV¡BPEGASYS©Î¬O¦bGENENTECH ¥Ó½ÐPegasy¸É§U¨Ï¥ÎªºPV±wªÌ¡AÀ³¸Ó·|¶V¨Ó¶V¦hÂà¦VPAN ©Îgood days¥Ó½Ð¸É§U¨Ï¥ÎBESREMI¡C¦P®É¡A¥¼¥Ó½Ð¸É§UPV±wªÌ¡A¥ç¬O·|¶V¨Ó¶V¦hª½±µ¦VPAN ©Îgood days¥Ó½Ð¸É§U¨Ï¥ÎBESREMI¡C

°Ñ¦Ò¸ê®Æ¡G

¤@¡Bwww.panfoundation.org/

¤G¡Bwww.mygooddays.org/patients/diseases-covered/myeloproliferative- diseases

¤T¡Bwww.gene.com/patients/patient-foundation

¥|¡BMPN¬ÛÃöªÀ¸s

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2022/1/9 ¤W¤È 09:40:35²Ä9968½g¦^À³
½Ã¥Í³¡ (VM) ¤w¹ïªk°|µô¨M´£¥X¤W¶D¡A¸Óµô¨M¤ä«ù¤@¦W¸~½F±wªÌ­n¨D±q°ê®a¹wºâ¤¤¤ä¥I²{¥NÃĪ«¶O¥Î¡C

¸Ó³¡¦b¦V·s»Dªù¤áºô¯¸ LSM.lv ¸ÑÄÀ¹ï§P¨M´£¥X¤W¶Dªº¨M©w®Éªí¥Ü¡Aªk°|±o¥X¤F¿ù»~ªºµ²½×¡A³o»P¾Ëªkªk°|ªº½Õ¬dµ²ªG¬Û¥Ù¬Þ¡Cªk°|ÁÙ¦±¸Ñ¤Fªk³W¤¤Ãö©ó¥i³ø¾PÃÄ«~»s«×©Ê½èªº³W©w¡C

½Ã¥Í³¡ªí¥Ü¡A³ø¾P¨î«×¦³¨âºØ³ø¾P¾÷¨î¡G¤@¯ë³ø¾P©M­Ó¤H³ø¾P¡C¸Ó³¡»{¬°¡A¦a°Ï¦æ¬Fªk°|¦b¨ä§P¨M¤¤¨S¦³¦Ò¼{³o¨âºØ¾÷¨îªº©Ê½è¡A¦]¦¹¦bÂåÃIJ£«~ªº¤@¯ë³ø¾P¾÷¨î¥²¶·±Ä¨ú­Ó§O³ø¾Pµ{§Çªº±¡ªp¤U¡A¥¦¬O¿ù»~ªº¡C³QÀ³¥Î¡C

¥i³ø¾PÃĪ«²M³æ¥]¬A¨Ã¥]¬A¾A¥Î©óªvÀø¥Ó½Ð¤H¯S©w¶EÂ_ªº Hydrea¡C¬°¥Ó½Ð¤H½T©wªº¶EÂ_¥H¤Î¸Ó¯f¨Òªº©Ò¦³¨ä¥L±¡ªp¤£¯à³Qµû¦ô¬°¿W¯Sªº¡A¦]¬°¦b©Ô²æºû¨ÈÁ`¦@¦³¤j¬ù 600 ¦W±wªÌ­Ñ¦³¬Û¦Pªº¶EÂ_¡C

¬°¤F«OÃÒ©Ò¦³±wªÌ¥u¨Ï¥Î¤@ºØÃĪ« Besremi ªvÀøªºÅv§Q¡A»Ý­n 4320 ¸U¼Ú¤¸¨Ó³ø¾P¸ÓÃĪ«¡A

¦pªG¦b½Ã¥Í³¡­pºâªºÃÄ«~¤@¯ë³ø¾P½d³ò¤º³ø¾P¡C2021¦~ÃÄ«~³ø¾P¨t²ÎªºÁ`¹wºâ¬°1.7»õ¼Ú¤¸¡C

¡§³o·N¨ýµÛ 600 ¦W³Q¶EÂ_¬°¯u©Ê¬õ²Ó­M¼W¦h¯gªº±wªÌ±N¤£±o¤£ªá¶O¤j¬ù¥|¤À¤§¤@ªº°ê®a¹wºâ¥Î©óÃĪ«³ø¾P¨t²Î¡A¨Ã¥B¤£±o¤£©ñ±ó¥þ³¡©Î³¡¤ÀÃĪ«¡A¨Ò¦p¤ßż¯f±wªÌ©Î¿}§¿¯f±wªÌ¡A ¡§¸Ó³¡¦b¤@¥÷Án©ú¤¤»¡¡C

§Y¨Ï³o¨ÇÃĪ««ö­Ó¤H³ø¾P¡A³o 600 ¦W±wªÌ¤]»Ý­n 850 ¸U¼Ú¤¸¡C³o¤ñ­Ó¤HÃÄ«~³ø¾Pªº©Ò¦³¸êª÷°ª¥X 2.5 ­¿¡C

»y¹Ò¡G

¦@¦³ 7 ¦W¸~½F±wªÌµ´±æ¦a°_¶D¸Ó¦{¡A­n¨DÀò±oªvÀø¬õ²Ó­M¼W¦h¯g©Ò»ÝªºÃĪ«¡C°ê®a¥u¬°¥i³ø¾PÃĪ«²M³æ¤WªºÃĪ«¥I¶O¡A¦ý¥¦­Ì¨Ã¤£Á`¬O¾A¦X±wªÌ¡CLīga Pumpuriņa »P°ê®aªº°«ª§¬O¦³¥Øªºªº¡A¦b¤W¶D®×¥ó¤¤¡A¦æ¬F°Ï°ìªk°|µô©w½Ã¥Í³¡¤£³ø¾P¥²­nÃÄ«~ªº ¨M©w¬O«Dªkªº¡C

www.lsm.lv/raksts/zinas/latvija/vm-parsudz-tiesas-spriedumu-par-musdienigu-onkologijas-zalu-apmaksu.a437965/

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2022/1/7 ¤W¤È 11:13:09²Ä9967½g¦^À³
¤@¡BÃĵØÃĦ۱q2021¦~11¤ë13¤é¨ú±o¬ü°êFDAÃÄÃÒ«á¡A¬ü°êPVº¯³z²v¸Û¦p¤½¥q©Ò¨¥¡APV±wªÌªº«OÀIÂл\°·¥þ¡AP1101®Ö­ã²Ä¤@¤Ñ¶}©l´N¥i¥H«OÀIµ¹¥I¡AÃĵØÃĹw­p¦b6­Ó¤ë¤º¦³80%ªº«OÀIÂл\²v¡C¥Ø«e¬ü°êÂåÀø«OÀI¤½¥q±NBesremi¯Ç¤JÃÄ«~²M³æ¡A­p¦³AlaskaCare Retiree DC Plan ¡BWestern Health ¡BUnitedHealthcare Oxford ¡BCoordinated Care¡BKaiser Permanente¡BHealthPartners¡BAnthem BlueCross¡BHealth Alliance¡BBlueCross BlueShield

TUFTS HEALTHµ¥(ÁÙ¦³¨ä¥L, ¸ê®ÆµLªk¤U¸ü)¡A·PıÃĵØÃĹw­p¦b6­Ó¤ë¤º¦³80%ªº«OÀIÂл\²v¡A¦n¹³¦³¥i¯à¹F¼Ð¡C

¤G¡B¨C¤éMPN¯f¤ÍªÀ¸s¡A°Q½×©Î¨Ï¥ÎBesremi¤H¼Æ¦³¤éº¥¼W¥[¡A¨C¤ëÀ禬¼W¥[¥i´Á«Ý¡A¦ý·|¼W¥[¦h¤Ö¡A©|«ÝÆ[¹î¡C

¤T¡B«ØÄ³¤½¥q¨p¶Ò®×¡A±N¤í¯Ê¸êª÷¡A¤@¦¸¸Ñ¨M´M§ä«D­ì¦³ªÑªF¡A§äµ¦²¤¦X§@§ë¸ê¤H¡A¡u±j±jÁp¤â¡v¦p¤¤¥~¥Í§Þ§ë¸ê°òª÷¡B¤j«¬ªk¤H¡B¥~°êÂåÃĤ½¥qµ¥¤JªÑ¡A¦³§U©óÄw½Xí©w¡AªÑ»ù¤Wº¦¡B±j¤Æ¥«³õ«H¤ß¡A¾¨§Ö¤Æ¸Ñ¥«³õ¹ï¨p¶ÒªººÃ¼{¤ÎÂø­µ¡C

¥|¡BBesremi¦b¬ü°êÂåÀø«OÀI¤½¥q¤ÎPV¨Ï¥Îº¯³z²v¤é¯q¼W¥[¡A¦ý¥Ø«e¤£«OÃÒÃĵØÃĤ½¥qªÑ»ù·|¤Wº¦¡A§ë¸ê§PÂ_¶R½æ½Ð¦Û¦æ­t³d¡C

¤­¡B·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¡¯¡¯¡¯¬ü°êÂåÀø«OÀI¤½¥q²¤¶

¤@¡BUnitedHealth Group¡]Áp¦X°·±d«OÀI¡^

1977¦~³Ð¥ß¡AÁ`³¡³]©ó©ú¥§Ä¬¹F¦{¡A¬O¬ü°ê³Ì¤jªº°·±d«OÀI¤Î½Ã¥Í¸ê°T¬ì§Þ¤½¥q¡AºX¤U¥]§tUnitedHealthcare¡BOvations¡BAmeriChoice¡BUniprise¡BSpecialized Care Services ©MIngenix¡C2012¦~³QFORTUNÂø»xµû¿ï¬°¬ü°ê«OÀI©MºÞ²z¦¡·ÓÅ@¤½¥q¤¤³Ì¨ü·q­«ªº°·±d«OÀI¤½¥q²Ä¤@¦W¡C¥Ø«e¬ù¦³7500¸U¦W§ë«O¤H¡AªA°È¦a°Ï²[»\¥þ¬ü50­Ó¦{¤Î50¦h­Ó°ê®a¡C

¤G¡BKaiser Permanente¡]³ÍÂÄÂåÀø¾÷ºc¡^

¦¨¥ß©ó1945¦~¡AÁ`³¡¦ì©ó¥[¦{¶ø§JÄõ¡A²[»\Kaiser Foundation Health Plans («DÀç§Q¤½¦@ÂåÀø²Õ´)¡BKaiser Foundation Hospitals («DÀç§Q¤½¦@ÂåÀø²Õ´) »PPermanente Medical Groups (Àç§QÂåÀø²Õ´)¡A¾Ö¦³910¸U¦W§ë«OªÌ¡B17,425¦ìÂå¥Í¡B48,285¦ìÅ@¤h¡B38­ÓÂåÀø¤¤¤ß©M608­ÓÂåÀø¿ì¤½«Ç¡C¦b«X°Ç©£¦{¡B¥[§QºÖ¥§¨È¦{¡B¬ìù©Ô¦h¦{¡B°¨¨½Äõ¦{¡BµØ²±¹y¦{¡B¥±¦N¥§¨È¦{©M«n¤j¦è¬v¦a°ÏÀò±o³Ì°ª¾ãÅéÅéÅç¡A¤]¬O°ß¤@¤@®a¦b¦h­Ó¦a°Ïűo³Ì°ª¾ãÅéÅéÅ窺¤½¥q¡C

¤T¡BBlue Cross Blue Shield

Á`³¡¦ì©óªÛ¥[­ô¡ABlue Cross Blue Shield½Ï¥Í©ó1930¦~¥N¤j¿½±ø®É´Á¡A±q¼w¦{¹F©Ô´µ¥«¶}©l¡A·í®É·í¦a±Ð®v¨C¤ë¦V¨©°ÇÂå°|¤ä¥I50¬ü¤À«O¶O¡A¥iÀò±o21¤ÑÂå°|Å@²zªA°È¡F¦P¤@®É´Á¡A¬ü°ê¦è¥_ªu©¤¦a°Ïªº¥ï¤ì©M±ÄÄq¤u¤H¶}©l¦V·í¦aÂå¥Í¤ä¥I¤pÃB¤ë¶O¥HÀò±o´NÂåªA°È¡ABlue Cross Blue ShieldÂå«O­p¹º¥¿¦¡½Ï¥Í¡C§@¬°¬ü°ê³W¼Ò³Ì¤jÂåÀø«OÀI¾÷ºc¡ABlue Cross Blue Shield´£¨Ñªñ1»õ¦W§ë«O¤H(¬ù1/3¬ü°ê¤H¤f)¡AªA°È¦a°ìÂл\¥þ¬ü50¦{¡B­ô­Û¤ñ¨È¯S°Ï¤Îªi¦h¾¤¦U°UºÞ¦a¡C

¥|¡BIndependence Health Group

§@¬°Blue Cross Blue Shield¡A¦b¦h­Ó¦{´£¨ÑªA°È¡AAmeriHealth©MTandigm¤]¬OIHG®a±Ú¥ø·~ªº¤@³¡¤À¡A¬°¶W¹L830¸U¤H´£¨Ñ«OÀIªA°È¡A¨ä¤¤¥]¬A¶W¹L19000¦WÀ¦¨à¡A¾Ö¦³¶W¹L42000¦W°·±d±M·~¤H¤h¡AIndependence Blue Cross«ù¥d¤H¥i¥H¦b¶O«°ªºBlue Cross RiverRink§K¶O·Æ¦B¡C

¤­¡BAnthem

³Ð¥ß©ó1940¦~¥N¡A«e¨­¬OWellPoint, Inc.¡A©ó2014¦~12¤ë§ó§ï¬°²{¦W¡A¬O¬ü°ê²Ä¤G¤j°·±dÂåÀø«OÀI¤½¥q¡A¬ù¦³3750¸U«O¤á¡A¦b¥[¦{«h¦³830¸U¦W«O¤á¡A¦b¥[¦{¥sAnthem Bluecross ¬°¥[¦{¥«¦û²v³Ì°ªªºÂåÀø«OÀI¤½¥q¡CAetna ³Ð«Ø©ó1850¦~ªº±d¤D¨f§J¦{Hartford¡A¾ú¸g¥@¬É¤j¾Ô»P¸gÀÙ¤j¿½±ø¡A¬°¥þ¬ü¾ú¥v³Ì±y¤[ªºÂåÀø«OÀI¤½¥q¡C°£¤F´£¨Ñ¦h¤¸ÂåÀø«OÀI¤è®×¡B¼u©Ê¤º®e»P¥i­t¾áªº«O¶O¿ï¾Ü¡AAetnaªº¥þ¬üÂåÀøºôµ¸¦³¶W¹L458,000¦WÂå®v¡B4,681¶¡Âå°|¡CªA°È¦a°Ï²[»\¥þ¬ü50¦{¡C

¤»¡BHumana¡]«¢ªù¨º¤½¥q¡^

¤£³q¹LACA¡]±wªÌ«OÅ@»P¥­»ùÂåÀøªk®×¡^¥X°â­Ó¤H°·±d«OÀI­p¹º¡A¥u¦³¦ì©ó«n³¡ªº¥D­n°·±d«OÀI¤½¥q¡]ªÖ¶ð°ò¦{ªº¸ô©ö´µºûº¸¡^¤½¶}¤ä«ù­t³d¥ôªºÂåÀø¤ä¥I¼Ò¦¡¡AÂå¥Í¦b«O»Ù±wªÌ°·±d¤è­±°µ±o«Ü¦n¡A¾¨ºÞÀ²¼Ð¦rÅé¬Ý°_¨Ó¦³ÂI©_©Ç¡A¦ý¤´µM«Ü®e©öÃѧO¡A¼w§JÂÄ´µ¦{³Ì¦nªº¾ãÅéÅéÅç¡F«X¥è«X¦{³Ì¦nªº«O»Ù©MºÖ§Q¡F¥ì§Q¿Õ¥ì¦{©M¦L²Ä¦w¯Ç¦{³Ì¦nªº¥æ¬y³q°T¡C

¤C¡BHealth Care Service Corporation

Health Care Service Corporation¬O¥ì§Q¿Õ¥ì¦{¡B»X¤j®³¦{¡B·s¾¥¦è­ô¦{¡B«X§J©Ô²ü°¨¦{¡A¥H¤Î¼w§JÂÄ´µ¦{ªºBlue Cross Blue Shield¡]ÂŤQ¦rÂŬިó·|¡^´£¨Ñ°Ó¡A¾Ö¦³¶W¹L233000¦WÂåÀøªA°È´£¨ÑªÌ¡AÀò±oEthisphere Institute¹{µoªº¥þ²y³Ì¨ã°Ó·~¹D¼w¥ø·~¼ú¾Ö¦³ªñ1500¸U¦W·|­û¡A¬O³Ì¤jªº«D§ë¸êªÌ±±¨îªº°·±d«OÀI¤½¥q¡A¥ì§Q¿Õ¥ì¦{³Ì°ª¾ãÅéÅéÅçµû¤À¡F¦òù¨½¹F¦{³Ì°ª«È¤áªA°Èµû¯Å¡C

¤K¡BCentene

¾Ö¦³Ambetter¡BHealth Net©MFidelis CareÂåÀø«OÀI¤½¥q¡A·|­û¼Æ¶q¶W¹L1200¸U¡ACentAccount­p¹º¦V²Å¦X±ø¥óªº·|­û´£¨Ñ¤pÃB¤ä¥I¡A¥HÀò±o§K¶O°·±dÀˬd©ÎªÌÀù¯gÀˬd¡A¦b¤ºµØ¹F¦{¡BµØ²±¹y¦{µ¥«Ü¦h¦a°Ï¡A¥H¤Î¨ä¥L«OÀI¤½¥q°±¤î¾P°â­Ó¤H¶ø¤Ú°¨Âå§ï­p¹ºªº¦a°Ï´£¨Ñ°·±d­p¹º¡C

¤E¡BCigna¡]«H¿Õ¶°¹Î¡^

³Ð¥ß©ó1792¦~©ó»«¦{¡A¦P¼Ë¬°¬ü°ê³Ì±y¤[°·±d«O¤½¥q¤§¤@¡A¬O¥ÑInsurance Company of North America©MComnecticut Gcncral Life¦X¨Ö¦Ó¦¨¡CCignaªº«e¨­Insurance Company of North America¬O²Ä¤@®aÀò­ã¦b¤¤°ê¸gÀç«OÀI·~°Èªº¬ü°ê«OÀI¤½¥q(1897¦~)¡CAnthem©ó2015¦~7¤ë±ý¥H¶W¹L480»õ¬ü¤¸¦¬ÁÊCigna¡A¦¨¬°¬ü°êÂåÀø«O°·¦æ·~¨ÖÁʼ餤³Ì¤jªº¤@µ§¥æ©ö¡CµM2017¦~2¤ë¬ü°êºÊºÞ¾÷ºc¨Ã¥¼§å­ã¨ÖÁʮסC

¸ê®Æ¨Ó·½¡G

www.tigerless.com/american-health-insurance/

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2022/1/7 ¤W¤È 08:00:38²Ä9966½g¦^À³
¤@¡B¸É¥R¸ê®Æ¡G(­Y¦³¿ù»~¡A¥HÃĵØÃĤ½¥q¥¿¦¡¤½§i¬°·Ç)¡C

(¤@)AlaskaCare Retiree DC Plan Prescription Drug Formulary

BESREMI

Drug Tier¡G3(Highest-cost)

Requirements/Limits¡GSP(Specialty Medication)

mail.google.com/mail/u/0/?tab=rm&ogbl#inbox?projector=1

(¤G)Your 2021 Western Health Advantage 3-Tier Preferred Drug List

BESREMI SUBCUTANEOUS SOLUTION PREFILLED

SYRINGE 500 MCG/ML (ropeginterferon alfa-2b-njft)

Coverage Requirements &Limits: PA

doc-0o-4k-apps-viewer.googleusercontent.com/viewer/secure/pdf/bbsdnmudv7bk969gc31mekr52aesn5oi/apjrku632c63tghvktkd0okad5ipshcs/1641513225000/gmail/10341448784053036

¤G¡B¸ê®Æ¨Ó·½¡GMPN¬ÛÃöªÀ¸s

(¤@)I just got approved for Besremi! For those who have started on it recently, how is it going? Are side effects better on it as opposed to Peg? I¡¦ve been taking 27 mcg of Peg a week-not as effect as 45 but trying to keep the side effects to a tolerable level. How does that translate into the dosage of Besremi?

§Ú­è­èÀò±o Besremi ªº§å­ã¡I¹ï©ó¨º¨Ç³Ìªñ¶}©l¨Ï¥Î¥¦ªº¤H¨Ó»¡¡A¶i®i¦p¦ó¡H»P Peg ¬Û¤ñ¡A¥¦ªº°Æ§@¥Î¬O§_§ó¦n¡H§Ú¨C¶gªA¥Î 27 ·L§J Peg¡X¡X®ÄªG¤£¦p 45¡A¦ý¸Õ¹Ï±N°Æ§@¥Î«O«ù¦b¥i¥H§Ô¨üªº¤ô¥­¡C³o¦p¦óÂà¤Æ¬° Besremi ªº¾¯¶q¡H

(¤G)Me too! First dose tomorrow!

§Ú¤]¬O¡I©ú¤Ñ²Ä¤@¾¯¡I

(¤T)Does anyone know what the CIGNA ¡¨J-code¡¨ for BESREMi is? I¡¦ve an appointment with my doctor tomorrow for my first dose but they still don¡¦t know what the code or cost will be.

¦³½Öª¾¹D BESREMi ªº CIGNA ¡§J-code¡¨ ¬O¤°»ò¡H§Ú©ú¤Ñ©M§ÚªºÂå¥Í¹w¬ù¤F§Úªº²Ä¤@¾¯¡A¦ý¥L­Ì¤´µM¤£ª¾¹D¥N½X©Î¶O¥Î¬O¦h¤Ö¡C

(¥|)Feeling concerned¡K I¡¦m setting up to start Besremi (excited!)

·P¨ìÃö¤ß......§Ú¥¿¦b·Ç³Æ¶}©l Besremi¡]¿³¾Ä¡I¡^

·|­û:¥ý¶i10000164µoªí®É¶¡:2022/1/6 ¤U¤È 12:47:50²Ä9965½g¦^À³
¤ß¬O©Z¿º¿ºªº«ç»ò·|©È¤H»¡©O¡H¤j¸s²Õ¤@¨¥°ó.....¤ß¸Ì¦³°­
·|­û:§d°ê¥°10151930µoªí®É¶¡:2022/1/6 ¤U¤È 12:44:23²Ä9964½g¦^À³
Ãĵؤj¸s²Õ¦³285O¤H

¦³¤HÂà¶K¥ý¶i¤jªºµo¨¥

µ²ªG¬O³Q¬í§R

¨S³o¦^¬O?

¬°¤°»ò¦³¤Hı±o«Ü¨ë²´©O?

´N¤U­±³o½g

¤µ¤éÃĵØÃÄ12¤ëÀ禬Áٺ⤤¤W¡A¶i¨B¤¤.....³ºµM§Ë¥X¤@­Ó¶^°±

¬O¤£¬OÀ£»ù¤S·d¨p¶Òªº¤âªk¡A¯uªºÅý¥»¤H«ÜÃhºÃ¡A¨p¶Ò¬O§|±þ¤@¯ë§ë

¸ê¤H¹Ï§Q¥L¤Hªº¤âªk¡A³oÃĵØÃĤº³¡¸ò°­¨S¨â¼Ë¡AÄ~Äò¬Ý¤U¥h......

·|­û:¬Ý©x10141406µoªí®É¶¡:2022/1/6 ¤U¤È 12:28:18²Ä9963½g¦^À³
¥ý¶i¤j¡ã§Ö¹L¦~¤F ¬O¦b»°¶i«×°Õ⋯⋯
·|­û:¥ý¶i10000164µoªí®É¶¡:2022/1/6 ¤W¤È 10:46:58²Ä9962½g¦^À³
¤µ¤éÃĵØÃÄ12¤ëÀ禬Áٺ⤤¤W¡A¶i¨B¤¤.....³ºµM§Ë¥X¤@­Ó¶^°±

¬O¤£¬OÀ£»ù¤S·d¨p¶Òªº¤âªk¡A¯uªºÅý¥»¤H«ÜÃhºÃ¡A¨p¶Ò¬O§|±þ¤@¯ë§ë

¸ê¤H¹Ï§Q¥L¤Hªº¤âªk¡A³oÃĵØÃĤº³¡¸ò°­¨S¨â¼Ë¡AÄ~Äò¬Ý¤U¥h......

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2022/1/6 ¤W¤È 07:58:46²Ä9961½g¦^À³
¸É¥R¸ê®Æ¡G(­Y¦³¿ù»~¡A¥HÃĵØÃĤ½¥q¥¿¦¡¤½§i¬°·Ç)¡C

¤@¡BUnitedHealthcare Oxford Policy Update Bulletin: January 2022

Policy Title¡GDrug Coverage Guidelines¡GBesremi (Ropeginterferon-Alfa-2b-Njft)

Status¡GRevised¡C

Effective Date¡GFeb. 1, 2022

UnitedHealthcare Oxford ¬Fµ¦§ó·s¤½§i¡G2022 ¦~ 1 ¤ë

¬Fµ¦¼ÐÃD¡GÃĪ«Âл\«ü«n¡GBesremi (Ropeginterferon-Alfa-2b-Njft)

ª¬ºA ¡G ­×­q¡C

¥Í®Ä¤é´Á¡G2022¦~2¤ë1¤é

mail.google.com/mail/u/0/?tab=rm&ogbl#inbox?projector=1

¤G¡BNALC Health Benefit Plan Specialty Drug List

Medication Name¡GBesremi

Prior Approval Required: YES

Medication Obtained through CVS Specialty *:µL¡C

Step Therapy ¡GµL¡C

NALC°·±dºÖ§Q­p¹º±M¬ìÃÄ«~¥Ø¿ý

ÃĪ«¦WºÙ ¡G Besremi

»Ý­n¨Æ¥ý§å­ã¡G¬O

³q¹L CVS ±M¬ìÀò±oªºÃĪ« *¡GµL¡C

¶¥±èÀøªk¡GµL¡C

doc-10-4k-apps-viewer.googleusercontent.com/viewer/secure/pdf/bbsdnmudv7bk969gc31mekr52aesn5oi/gr7vjqi33vj4v5sgoo6e8336op4hja7p/1641425850000/gmail/10341448784053036761/ACFrOgAiDb-4S8-_utVSWcGVm-zPaQJhNVtCDujjvtLIwJ62u2m7RJXWHomNEJSynAIvddoC9TOTRpkEiXH4dx2nN_kQTZ7PLHDWkISFva9seu2r0X93BIGTKo39DGc=?print=true&nonce=and2skjq49frm&user=10341448784053036761&hash=urt4v4nbeauuv9anhoej9frj7pdo7iak

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2022/1/6 ¤W¤È 06:52:24²Ä9960½g¦^À³
¸ê®Æ¨Ó·½¡GMPN¬ÛÃöªÀ¸s

¤@¡BBESREMI UPDATE:

My hematologist sent my prescription to a pharmacy in Louisville, KY called Onco360. There, the pharmacists applied a grant to cover the entire cost of Besremi with a $0 co-pay. I received my first two vials in the mail yesterday, and it came with a large welcome packet, and some goodies from the pharmacy (lip balm, hand sanitizer, sunscreen, and lotion). I¡¦m waiting to begin injections until after I receive an eye exam (per instructions from my hematologist), but am so thankful I have this in my possession. If anyone with private insurance is waiting on coverage, PLEASE advocate with your pharmacy to see if you qualify for grant coverage like I apparently did. The pharmacy did not verify my income to make this available to me.

BESREMI §ó·s¡G§Úªº¦å²G¬ìÂå¥Í±N§Úªº³B¤è±Hµ¹¦ì©óªÖ¶ð°ò¦{¸ô©ö´µºûº¸ªº¤@®a¦W¬° Onco360 ªºÃĩСC¦b¨º¸Ì¡AÃľ¯®v¥Ó½Ð¤F¤@µ§ÃØ´Ú¡A¥H¤ä¥I 0 ¬ü¤¸ªº¦@¥IÃB¨Ó¤ä¥I Besremi ªº¥þ³¡¶O¥Î¡C¬Q¤Ñ§Ú¦¬¨ì¤F§Úªº«e¨â²~¶l¥ó¡A¸Ì­±¦³¤@­Ó«Ü¤jªºÅwªï¥]¡AÁÙ¦³¤@¨ÇÃĩЪº¦nªF¦è¡]¼í®B»I¡B¬~¤â²G¡B¨¾ÅÎÁ÷©M¨Å²G¡^¡C§Ú¥¿¦bµ¥«Ý±µ¨ü²´¬ìÀˬd¡]®Ú¾Ú§Úªº¦å²G¬ìÂå¥Íªº«ü¥Ü¡^¤§«á¤~¶}©lª`®g¡A¦ý§Ú«D±`·PÁ§ھ֦³³o­Ó¡C¦pªG¦³¨p¤H«OÀIªº¤H¥¿¦bµ¥«Ý©Ó«O¡A½Ð¦V±zªºÃĩЫŶǡA¬Ý¬Ý±z¬O§_¦³¸ê®æ¹³§Ú¤@¼ËÀò±o¸É§Uª÷©Ó«O½d³ò¡CÃĩШS¦³®Ö¹ê§Úªº¦¬¤J¨Ó´£¨Ñµ¹§Ú¡C

I just sent out my prescription yesterday. I¡¦m waiting on the approvals. Dr. Said it should take 2 weeks

§Ú¬Q¤Ñ­è±H¥X§Úªº³B¤è¡C§Ú¥¿¦bµ¥«Ý§å­ã¡CÂå¥Í»¡À³¸Ó»Ý­n 2 ¶g

Mine took two weeks as well. Good luck!¡¦

§Úªº¤]ªá¤F¨â¶g¡C¯¬§A¦n¹B¡I

¤G¡BBesremi Approval Saga - SUCCESS!

I am very pleased to report success in getting Besremi authorized by my Cigna Medicare Rx - Medicare Part D plan. The original denial contained the statement There are no conditions under which this request would be approved under Medicare part D. It took about 6 hours of repeated phone calls to various Cigna Departments but persistence overcame resistance.

For those is a similar circumstance, there are two things that seem to have worked to get past the initial denial and first level appeal denial.

1. I filed a formal Medicare Grievance due to Cigna not providing a copy of the Plan Rules on which the denial was based and denying access to Besremi.

2. I kept calling back to the Cigna Appeals division seeking the information needed to file an appeal. In my last call, the customer service representative identified that Cigna had made a mistake. They originally referred the appeal to an Administrative Review when this should have been a Medical Coverage Review. This should have been handled as a Formulary Coverage Review requesting authorization for a medication not on the formulary.

Cigna faxed a new appeal form to the doctor who prescribed the Besremi. When he contacted Cigna they told him it had already been approved. The doc called me to tell me and said the approval was not the result of anything they had done. Cigna contacted me moments later to notify me of the authorization.

The next step is for Biologics to contact me to arrange shipping. I have three doses of Pegasys left, which I will use up before starting the Besremi. I am planning to follow Dr. Mesa¡¦s recommendation for the starting dose for someone stable on 45mcg/week of Pegasys - 63mcg/every-other-week of Besremi. We will see how that goes. As it turns out the switch from Pegasys to Besremi was not researched so it really is going to be trial-and-error. I am fine with being a Beta-tester for doing the switch. It is the only way we will learn.

To all those who encounter denials of Besremi or any other medication needed to treat their MPN or other condition - do not give up! We may not always succeed due to persistence, but we will always fail when we do not persist. We must be our own best advocates.

All the best to all of you and continued success in accessing the care we all need and deserve.

Besremi §å­ã¶Ç©_ - ¦¨¥\¡I

§Ú«Ü°ª¿³¦a³ø§i Besremi ¤wÀò±o§Úªº Cigna Medicare Rx - Medicare Part D ­p¹ºªº±ÂÅv¡C³Ìªìªº©Úµ´¥]§t³o¼ËªºÁn©ú¡G¡§®Ú¾ÚÂåÀø«OÀI D ³¡¤À¡A¨S¦³¥ô¦ó±ø¥ó¥i¥H§å­ã¦¹½Ð¨D¡C¡¨ ªá¤F¤j¬ù 6 ­Ó¤p®É¤ÏÎ`¼·¥´ Cigna ¦U­Ó³¡ªùªº¹q¸Ü¡A¦ý°í«ù§JªA¤Fªý¤O¡C

¹ï©ó¨º¨ÇÃþ¦üªº±¡ªp¡A¦ü¥G¦³¨â¥ó¨Æ¥i¥H§JªAªì©l©Úµ´©M¤@¯Å¤W¶D©Úµ´¡C

1. ¥Ñ©ó Cigna ¥¼´£¨Ñ©Úµ´©Ò¨Ì¾Úªº­p¹º³W«h°Æ¥»¨Ã©Úµ´³X°Ý Besremi¡A§Ú´£¥æ¤F¥¿¦¡ªº Medicare ¥Ó¶D¡C

2. §Ú¤@ª½µ¹ Cigna ¤W¶D³¡ªù¥´¹q¸Ü¡A´M¨D´£¥X¤W¶D©Ò»Ýªº«H®§¡C¦b§Ú³Ì«á¤@¦¸³q¸Ü¤¤¡A«È¤áªA°È¥Nªíµo²{ Cigna ¥Ç¤F¤@­Ó¿ù»~¡C¥L­Ì³Ìªì±N¤W¶D´£¥æµ¹¦æ¬F¼f¬d¡A¦Ó³o¥»À³¬OÂåÀø«OÀI¼f¬d¡C³oÀ³¸Ó§@¬°³B¤èÃÄÂл\²v¼f¬d¨Ó³B²z¡A­n¨D¹ï¤£¦b³B¤èÃĮѤ¤ªºÃĪ«¶i¦æ±ÂÅv¡C

Cigna ¦V¶} Besremi ³B¤èªºÂå¥Í¶Ç¯u¤F¤@¥÷·sªº¤W¶Dªí¡C·í¥LÁpô Cigna ®É¡A¥L­Ì§i¶D¥L¥¦¤w¸gÀò±o§å­ã¡CÂå¥Í¥´¹q¸Ü§i¶D§Ú¡A¨Ã»¡§å­ã¤£¬O¥L­Ì©Ò°µªº¥ô¦ó¨Æ±¡ªºµ²ªG¡C¤£¤[¤§«á¡ACigna Ápô¤F§Ú¡A³qª¾§Ú±ÂÅv¡C

¤U¤@¨B¬O Biologics »P§ÚÁpô¥H¦w±Æ¹B¿é¡C§ÚÁٳѤT¾¯ Pegasys¡A§Ú±N¦b¶}©l Besremi ¤§«e¥Î§¹¡C§Ú­p¹º¿í´` Mesa ³Õ¤hªº«ØÄ³¡A¹ï©ó 45 ·L§J/¶g Pegasys - 63 ·L§J/¹j¶g Besremi í©wªº¤Hªº°_©l¾¯¶q¡C§Ú­Ì±N¬Ý¨ì±¡ªp¦p¦ó¡C¨Æ¹êÃÒ©ú¡A±q Pegasys ¨ì Besremi ªºÂà´«¨Ã¥¼¸g¹L¬ã¨s¡A¦]¦¹½T¹ê»Ý­n¤Ï½Æ¸ÕÅç¡C§Ú«Ü°ª¿³¦¨¬°¶i¦æÂà´«ªº¡§Beta ´ú¸Õ¤H­û¡¨¡C³o¬O§Ú­Ì¾Ç²ßªº°ß¤@³~®|¡C

¹ï©ó©Ò¦³©Úµ´±µ¨ü Besremi ©ÎªvÀø MPN ©Î¨ä¥L¯e¯f©Ò»Ýªº¥ô¦ó¨ä¥LÃĪ«ªº¤H - ¤£­n©ñ±ó¡I§Ú­Ì¤£¤@©w·|¦]¬°°í«ù¦Ó¦¨¥\¡A¦ý¦pªG§Ú­Ì¤£°í«ù¡A§Ú­Ì±N¥Ã»·¥¢±Ñ¡C§Ú­Ì¥²¶·¦¨¬°¦Û¤v³Ì¦nªº¾ÖÅ@ªÌ¡C

¯¬¤j®a¤@¤Á¶¶§Q¡A¨Ã¦bÀò±o§Ú­Ì©Ò¦³¤H³£»Ý­n©MÀ³±oªºÅ@²z¤è­±Ä~Äò¨ú±o¦¨¥\¡C

Good luck and God bless you ! I¡¦m waiting to begin it very soon myself, it¡¦s been approved for me as well I have United Healthcare. My doctor appointment is 1/11. Hopefully I will get it soon after that . I¡¦m praying it helps me because I¡¦m on three hydrox. a day and my platelets are still 1.2 million.

¯¬§A¦n¹B¡A¤W«Ò«O¦ö§A¡I§Ú¥¿¦bµ¥«Ý¦Û¤v«Ü§Ö¶}©l¡A¥¦¤]¤w¬°§Ú§å­ã¡A§Ú¦³ United Healthcare¡C§ÚªºÂå¥Í¹w¬ù¬O 1/11¡C§Æ±æ¦b¨º¤§«á§Ú·|«Ü§Ö±o¨ì¥¦¡C§Ú¬è륦¹ï§Ú¦³À°§U¡A¦]¬°§Ú¥¿¦bªA¥Î¤Tßm¦âÓi¡C¤@¤Ñ§Úªº¦å¤pªOÁÙ¬O120¸U¡C

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2022/1/5 ¤U¤È 05:28:47²Ä9959½g¦^À³
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Type : Bid Notification

Due : 03 Jan, 2022 (1 day ago)

Posted : 1 month ago

Started : 14 Dec, 2021 (21 days ago)

P&T COMMITTEE MEETING: February 2022: The following drug classes/subclass will be reviewed: Besremi ¡V Oncological Agents ¡V Subclass

From: Federal Government (Federal)

°ê¨¾³¡ÃĩвΤ@³B¤è¤@Åó¤lÁʶR¨óij/²Î¤@³B¤èªþ¥[§é¦©­p¹º

Ãþ«¬¡G§ë¼Ð³qª¾

ºI¤î¤é´Á¡G 2022 ¦~ 1 ¤ë 3 ¤é¡]1 ¤Ñ«e¡^

µoªí¡G 1 ­Ó¤ë«e

¶}©l®É¶¡¡G 2021 ¦~ 12 ¤ë 14 ¤é¡]21 ¤Ñ«e¡^

P&T ©e­û·|·|ij¡G2022 ¦~ 2 ¤ë¡G±N¼f¬d¥H¤UÃĪ«Ãþ§O/¨ÈÃþ¡G Besremi ¡V ¸~½FÃĪ« ¡V ¨ÈÃþ¡G

¨Ó¦Û¡GÁp¨¹¬F©²¡]Áp¨¹¡^

www.instantmarkets.com/q/besremi?ot=Bid%20Notification,Pre-Bid%20Notification,Award,Contract&pg=1&c=us&os=Active,Archived&defaultSearch=true

·|­û:§õÁ`²Î10135593µoªí®É¶¡:2022/1/5 ¤U¤È 02:39:35²Ä9958½g¦^À³
¤£¬O¨C­Ó¤H³£¬OÁo©ú¤H

¬Ý¦nÃĵØÂåÃĪº§ë¸ê¤H ©w¬O±M·~¤¤ªº±M·~

Àç·~ÃB©w¤ñ incy ¦n

¦h¤Ö©O °Ñ¦Ò¤W¦¸¬ü°ê¤ÀªR®v¹ï PTGX ªº¹w¦ô ¦Ó¥B P1101 ©w¯à¤ñ³oª÷ÃB°ª

¦]¬° PTGX¬O 1½u¥ÎÃÄ INCY¬O2½u ¦Ó P1101 ¬O¥þ½u¥ÎÃÄ

³o¼ËÀ´¤F»ò¶Ü ¦pªGÁÙ¤£À´´N¥h°Ý¶ý¶ý

·|­û:AronHsiao10139924µoªí®É¶¡:2022/1/5 ¤U¤È 01:24:05²Ä9957½g¦^À³
The scoop: PharmaEssentia¡¦s Besremi in November won approval to treat polycythemia vera, a rare disorder that slows blood flow and can cause clotting, heart attack and stroke. Besremi, which was co-developed by AOP Orphan of Austria and approved in Europe in 2019, is the first interferon treatment for the disease and the only drug that can be used for it regardless of treatment history. While Incyte¡¦s Jakafi is a second-line therapy, Besremi can be applied upon initial diagnosis. The drug, which was launched on Dec. 6, is injected every two weeks and if effective, injections can be reduced. The Taiwan-based company has priced it at $180,000 for an annual regimen. Yuanta projects Besremi will add 800 patients each year in the U.S. and increase sales each year by $100 million. PharmaEssentia has more in mind for Besremi as it is investigating its effectiveness against essential thrombocythemia, myelofibrosis and chronic hepatitis.
·|­û:AronHsiao10139924µoªí®É¶¡:2022/1/5 ¤U¤È 12:23:24²Ä9956½g¦^À³
¦­¤W¬Ý¨ì¡A¦n¹³¬O°ê¤º¤¸¤jµoªíªº¡A°ê¤ºªk¤H¤@°ï²´¥úµu²L¤§¤H¡A±`±`¤£ª¾©Ò¤ª¡I

Ãĵجü°ê¹Î¶¤¬O·~¬Éµ×­^¡A¥[¤W¦³7.5¦~ªºÁ{§É¸ê®Æ¸òfda¥þ½u¥ÎÃĪº­I®Ñ¡A

Áٽ檺¤ñ¤G½uÃÄÁÙ®t¡H§Aı±o¥i¯à¶Ü¡H1­Ó¦h¤ëªº®É¶¡¡A«OÀI¤½¥q³°Äò¥[¤J²[»\¡A

³o2¤Ñ±qÀ禬´N¥i¥H¤@¿s¤@¤G¤F¡I¤£¾å±o§A¦p¦ó¬Ýªk

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2022/1/5 ¤W¤È 11:34:37²Ä9955½g¦^À³
¸É¥R«OÀI¡G(¸ê®Æ­Y¦³»~¡A½Ð¥HÃĵØÃĤ½¥q¥¿¦¡¤½§i¬°·Ç)

¤@¡BCoordinated Care

BESREMI

Requirements/Limits ¡GPA

FORMULARY-CoordinatedCare_Washington.pdf

¤G¡BÃĵØÃľP°âÃB(«O¦u¬Ýªk?)

2021¡¦s NDA list includes some extraordinary accomplishments. Hitting a new record on approvals was just one

½âª÷ÄÝ2021 ¦~ªº NDA ²M³æ¥]¬A¤@¨Ç«D¤Zªº¦¨´N¡C³Ð¤U¼f§å·s¬ö¿ý¥u¬O¨ä¤¤¤§¤@

2022 ¦~ 1 ¤ë 4 ¤é

(ºK¿ý)

Company: PharmaEssentia Corporation

Price: $180,000 per year

Peak sales estimate: $900 million by 2030

Approval date: 11/12/2021

¤½¥q¡GPharmaEssentia Corporation

»ù®æ¡G¨C¦~ 180,000 ¬ü¤¸

³Ì°ª¾P°âÃB¦ô­p¡G¨ì 2030 ¦~¹F¨ì 9 »õ¬ü¤¸

§å­ã¤é´Á¡G11/12/2021

PharmaEssentia faces an entrenched competitor in the space, Incyte¡¦s Jakafi in the US, approved in 2014. Its second-line treatment status though may give Besremi an edge in the $1.1 billion PV market. Besremi does come with a black box warning though with risk of serious disorders from interferon alfa products including fatal or life-threatening neuropsychiatric, autoimmune, ischemic and infectious disorders. ¡X Beth Snyder Bulik¡C

PharmaEssentia ¦b¸Ó»â°ì­±Á{µÛ¤@­Ó®Ú²`¸¦©TªºÄvª§¹ï¤â¡A§Y¬ü°ê Incyte ªº Jakafi¡A¸Ó²£«~©ó 2014 ¦~Àò±o§å­ã¡C¤£¹L¡A¨ä¤G½uªvÀø¦a¦ì¥i¯à·|Åý Besremi ¦b»ù­È 11 »õ¬ü¤¸ªºPV¥«³õ¤¤¦û¾ÚÀu¶Õ¡CBesremi ½T¹ê±a¦³¶Â®ØÄµ§i¡A¾¨ºÞ¤zÂZ¯À alfa ²£«~¦³¾É­PÄY­«¯e¯fªº­·ÀI¡A¥]¬A­P©R©Î¦M¤Î¥Í©Rªº¯«¸gºë¯«¯e¯f¡B¦Û¨­§K¬Ì©Ê¯e¯f¡B¯Ê¦å©Ê©M¶Ç¬V©Ê¯e¯f¡C¡X¨©µ·•´µ©`¼w•¥¬§Q§J

www.nxtmine.com/news/articles/base-metals/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/

·|­û:¬Ý©x10141406µoªí®É¶¡:2022/1/4 ¤U¤È 10:35:28²Ä9954½g¦^À³
ÃĵØÃħä¤F´X­Ó¦W¤H´N·Q»´»´±a¹L¡H

±q90¤¸ªº¨p¶Ò¦Ü177¤¸³o¦¸ªº235¤¸¥h¬d¤@¤U¦W³æ

¦Ê¤À¤§¤»¤Q³£¬O¥_³¡¬Y¤W¤s­Ñ¼Ö³¡ªº¤H­û

«D¬O¬F°Ó¦W¬y©Î¥Í§Þ¬É¤H¤h©Î¥ø·~ ¦p¬O³o¼Ë¹ï¤½¥qªø»·µo®i¼ç¤O¦³À°§U

¦ý¬O´N¬O¤@¯ëªº°h¥ð¤H­û¡A¹ï¤½¥qÀç¹B¼vÅT¦³¦h¤jÀ°§U©M·N¸q¡H

µo­Ó¼s§i¤å¦w¼­¤pªÑªF´N·Q¥i¥H¦A¨Ó¤@¦¸¡H

Âû³J¦A±K¤]¬O¦³Á_¡A¤½¥q¬£§O¦Ñ·QµÛ¹Ï§Q©T©w¯S©w¤H

·|­û:wu701610136601µoªí®É¶¡:2022/1/4 ¤U¤È 09:58:16²Ä9953½g¦^À³
ÃĵØÃÄ2¦¸¨p¶Ò¤j¦¨¥\ ¤k¯«±i¶vÚ¬¡B¥x¥_101¸³®y±i¾ÇµÏ³£°Ñ¥[

2022/01/04 19:27:48

¸gÀÙ¤é³ø °OªÌ¦ó¨q¬Â¡þ¥x¥_³ø¾É

·sÃĤWÂd¤½¥qÃĵØÃÄ¡]6446¡^¥h¦~12¤ë¡A¦b¤ëÀY¸ò¤ë§À¦U¿ì¤F¤@¦¸¨p¶Ò¡A¨â¦¸¨p¶Ò¤@¦@¶Ò¶°¨ì27.3»õ¦h¤¸ªº¸êª÷¡A¬Ý¦b¤£¤Ö±Mªù¨ó§U¥ø·~Äw¸êªº·|­p®v¡B«ß®v²´¤¤¡A°µ±o¬Û·íº}«G¡A¡uÃĵØÃÄ11¤ë¦b¬ü°ê¨ú±oÃÄÃÒ¡Aºò±µµÛ¦b12¤ë´N¦³¨â³õ¨p¶Ò¡A®É¶¡ÂI§ì±o«ê¨ì¦n³B¡Aºâ¬O¶Ò±o«Ü¦¨¥\¡I¡v

ÃĵØÃĦb¬ü°ê¨ú±oªºÃÄÃÒ¡A¬O±MªùªvÀø¡u¯u©Ê¬õ¦å²y¼W¦h¯g¡v¡]PV¡^·sÃÄRopeginterferon alfa-2b¡]P1101¡^¡A¥h¦~11¤ë13¤éÀò¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^®Ö¥i¤W¥«¡A¦¨¬°²Ä¤@­ÓÀòFDA®Ö­ãªºPV¤@½u¥ÎÃÄ¡C

ÃĵØÃĪñ¨ÓªÑ»ù¥i»¡¤Wºt¤jÅå©_¡A¥h(2021)¦~10¤ë7¤é¡AÃĵØÃĪѻù±q³Ì§C»ù69¤¸°_º¦¡A12¤ë14¤é´¿¨Ó¨ì422¤¸·s°ª»ù¡Aªñ¤T­Ó¤ë¨Ó¡AªÑ»ùº¦´T¤w¹F204%¡C¤µ¦~1¤ë3¤é³s°²«áªº¶}¤u­º¤é¡AªÑ»ù¥H264¤¸¶^°±§@¦¬¡A»á¦³¦^Àɸñ¶H¡A¦ý¬O¤´¦³¤£¤Ö¤H¬Ý¦nÃĵØÃĪº¥¼¨Ó¡C

2¦¸¨p¶Ò §l¤Þ¤£¤Ö¬F°Ó¦W¬y

®Ú¾Ú¤½¶}¸ê°TÆ[´ú¯¸¸ê®Æ¡A¤ñ¸ûÃĵØÃĪº¨â¦¸¨p¶Ò¡A¦³¤£¤Ö¬F°Ó¦W¬y°Ñ»P¨ä¤¤¡C²Ä¤@¦¸°Ñ»P¨p¶ÒªÌ¡A¥D­n¦³ÃĵØÃĸ³¨Æ»PªÑªF¡AÁÙ¦³ª¾¦WªA¸Ë³]­p®v½²©s®L»â­xªºÀs²Ã¹ê·~¡C

²Ä¤G¦¸¨p¶Ò¡A§ó¥i¬Ý¨ì¡A¥H­Ó¤H¦W¸q°ÑªÑªº¥x¥_101²{¥ô¸³¨Æªø±i¾ÇµÏ¡AÁÙ¦³¤k¯«¯Åºt­û±i¶vÚ¬¡A«e¹ü¤Æ¿¤ªø¨ô§B·½¡A¥H¤ÎÁé¤s§ë¸êªÑ¥÷¦³­­¤½¥q¡A³£°Ñ¥[¨p¶Ò¡CÁé¤sªº­t³d¤H¡A«h¬OµØ©T«Ø³]¡]2548¡^¸³®yÁéºa©÷¤§¤lÁé¨ô§g¡C

´¿¦h¦¸¨ó§U¥ø·~¨p¶Òªº«ß®vªí¥Ü¡A¤@¯ë¥ø·~¿ì¨p¶Ò¡A¦h·|¦hºÞ»ô¤UÁܬù§ë¸ê¤H¡A¦³¦W¤H¥[«ù¡A¹ï¤½¥q¨Ó»¡¡A¥i¥H³Ð³y¥úÀô®ÄÀ³¡C

¦Ü©óÃĵØÃÄ«h»¡¡A¸Ó¤½¥q¤£±Ä¤½¶}¶Ò¶°¡A¦Ó¬O¥Ñ¨p¶Ò¶Ò¸ê¡A¥D­n¬O¦Ò¶q¨p¶Ò¨ã®É®Ä©Ê»P«K§Q©Ê¡A¥B¨p¶Ò¦³»ùÃÒ¨é¤T¦~¤º¤£±o¦Û¥ÑÂàÅý¡A¯à½T«O¤½¥q»PÀ³¶Ò¤H¶¡ªºªø´ÁÃö«Y¡C

©È³QK¡H°êµo°òª÷°û©Ú°Ñ¥[¨p¶Ò

­È±oª`·Nªº¬O¡A­ì¥»ÃĵØÃÄÄÝ·N¤jªÑªF¤§¤@ªº°êµo°òª÷¡A¤]¨Ó°Ñ¥[¨p¶Ò¡A¦ý¬O´¿¸g¦n´X¦¸³Q¥ß©e®üK¡u¶Ã§ë¸ê¡vªº°êµo°òª÷¡A³o¦¸«o¬O«Ü§C½Õ¡A°û©Ú¤F³o¦¸¨p¶Ò¡C

°êµo°òª÷°õ¦æ¯µ®ÑĬ¨Ó¦u¦b±µ¨ü¡m¸gÀÙ¤é³ø¡n¬dÃҮɪí¥Ü¡A°êµo°òª÷¤w§ë¸êÃĵØÃij\¦h¦~¡A¥i»¡¡u¤½¥q¦¨¥ß´X¦~¡A°êµo°òª÷´N§ë¸ê´X¦~¡v¡A¦ý¦]¬°ÃĵØÃĤw¸g¤WÂd¡A¥i¥H¦Û¤v¤Þ¤J¥~³¡§ë¸ê¤H¡A¤£»Ý­n¬F©²¨ó§U¡A¨p¶Ò¦ÛµM¤]¯à§ä¨ì¯S©w§ë¸ê¤H¡A¬F©²À³¸ÓÀ°§U§ó»Ý­nªº¤½¥q¡A©Ò¥H°êµo°òª÷¥h¦~¨Ã¨S¦³°Ñ»PÃĵØÃĪº¨p¶Ò®×¡C

¦Ü©ó±i¾ÇµÏ¡A¦³ª¾±¡¤H¤hªí¥Ü¡A±i¾ÇµÏ¤j¤âµ§»{ªÑªñ1,000±i¡A­Y¥HÃĵØÃĪñ´ÁªÑ»ù¨Ó¬Ý¡A¤â¤WªÑ²¼¥«­È¯}»õ¡C¤£¹L¡A°Ñ»P¨p¶ÒªºªÑÅv¡A¤T¦~¤º¤£±o¶R½æ¡A±i¾ÇµÏºâ¬O§ë¸ê¤FÃĵØÃĤT¦~ªº¥¼¨Ó©Ê¡C

°]¬F³¡ªí¥Ü¡A±i¾ÇµÏÁö¬O¥H©xªÑ¥Nªí¨­¤À¾á¥ô¥x¥_101¸³®y¡A¦ý¥L¥H­Ó¤H¨­¤À°Ñ»P¨p¶Ò¡A¨Ã¤£¹Hªk¡C¡m¸gÀÙ¤é³ø¡n³z¹L¥x¥_101ªºµ¡¤f¡A¸ß°Ý±i¾ÇµÏ¬°¦ó­n°Ñ»PÃĵØÃĨp¶Ò¡AºI¦ÜºI½Z«e¡A³£¥¼¨ú±o±i¾ÇµÏ¦^À³¡C

·|­û:§õÁ`²Î10135593µoªí®É¶¡:2022/1/4 ¤U¤È 02:09:52²Ä9952½g¦^À³
¦pªG§A¦³¥Î¤ßÃö¤ß¹L¤½¥q ©Î³\§Aªº°ÝÃD´N¤£¬O°ÝÃD
·|­û:¥ý¶i10000164µoªí®É¶¡:2022/1/4 ¤W¤È 11:46:55²Ä9951½g¦^À³
Dreamtiger¤È¦w~¹ï©ó±zµL°í«ùÄ~Äò«ù¦³·P¨ì¥i±¤¡Aªø»·¨Ó¬ÝÃĵØÃīᥫÁÙ¬O²`¨ã«H¤ß¡A¦ý¤½¥q¬£¹ï¨p¶Ò¤@®×¤w¤Ó¦h¦¸ªº¬¢©T©w¤H¤h

¹ï©óªø´Á«ù¦³ªº­ì©lªÑªF¬O¶Ë®`¡A¤µ¤Ñ³o¿´¤j²î¤w±NÁÚ¤J¥¿­y¡AÀ³¦P¦à¦@ÀÙ¦³ºÖ¦@¨É¡AÃĵØÃÄ­Y¤z¦~«á¦³¬Õ¾l¡A¦AÀÀ¼·¤À¼í¼úª÷º¹½à

©Ò¦³¤½¥q­û¤u¡A©Ò¦³«ù¦³ÃĵØÃĪºªÑªF¤]¼Ö¨£¨ä¦¨¡A¦Ó«D¦b¨p¶Ò®×¤¤¹Ï§Q¡A«ØÄ³ÃĵØÃĤ½¥q¹ï©Ò¦³«ù¦³ªºªÑªF¤½¥­¹ï«Ý

·|­û:Dreamtiger10145627µoªí®É¶¡:2022/1/4 ¤W¤È 11:11:34²Ä9950½g¦^À³
¸ò¤F³oª©5¦~¦h~µ²ªGÁÙ¬O§Ô¤£¦í·Q°µªi¬q¦Ó¤U¨®(½æ¨ì180-160¨º¬q¯}¤­¤é«æ±þ)...

µ²ªGªi¬q¨S°µ¨ì´N¦^¸É¤£¤F¡A¤j·§¬O¯d¤F¨º»ò¤[ÁÙ¨SÁȨ쪺¤Ö¼Æ¤H§a(­ú..

»¡»¡¬°¤°»ò·Q°µªi¬q

1.¦]¬°¸g¾ú¹L´X¦¸º¦¤W¨Ó,µM«á§é¥b»ù¡A¤W¦¸¦³µo¨¥°Ý¬°¤°»ò¼Ú¬w½æ¤@¦~¤F¡AÁÙ¬O¤@©uÁ«3¤¸ªºª¬ºA¡A¨S¿ìªkª¾¹D¾ã­Ó¤½¥qÀç¹B¬O§_ÁÈ¿ú¡A¯uªºÅý§Ú¹ï¤½¥q¤@ª½µo¥¬¦n®ø®§«o¤@ª½Á«¿ú²£¥ÍÃhºÃ¡Aµ²ªG½æ±¼¤F¹j¤Ñ´N¶]¥X¨Ó»¡¤S¥X³f¤F2»õ ORZ

2.¸òanderson¤j¤@¼Ë¡A¬Ý¦n³o¤äÃÄ¡A«o¤£¬Û«H°ª¼hªº¡A¤pªÑªF¹ê¦b·í­´µæ³Î

3.¨C¦¸§Q¦hº¦¤@ÂI´N·|¶^»ù«Ü²`¡A¨C¦¸¬Ý½u«¬ªi¬q«oÁÙ¬O©ê¨c¡A¶Ë®`«Ü¤j(¥u¦³³o¦¸ÃÄÃÒ¦³ª£°_¨Ó)~µ²ªG³o¦¸§Ú«o³Q¬~¤F¥X¥h

4.ÁÙ¦³¬Y¨Ç­ì¦]Åý§Ú§ó°í«H³Î­´µæªº¦s¦b

¹ï©ó³o¦¸³s¥ý¶i¤j³£§Ô¤£¦íªº©ê«è¡A¹ê¦b·PIJ«Ü²`¡A¦pªG¬Y¨Ç¤H¯à±Mª`¦bÃľ¯¬ãµo¸ò±À¾P¡A¤£­n¦Ñ¬O·QºÉ¿ìªk³Î­´µæ¡A

À³¸Ó¤£·|µo¥ÍAOPªº¨Æ¥ó¡A¤]¤£·|Åý¬Û«H¥LªºªÑªF³Ì«á³£¤j½|¦Ó¥h

³Ì«áÁÙ¬O¯¬¤j®a¯àÁȱo¤¤ªø§Q¯q~¤p§ÌµL¤O¦^¸É´N¯¬ºÖ§A­Ì..ÃÄ«e´º«Ü¦n¡A«o¬O°¦§¯ªÑ..

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2022/1/4 ¤W¤È 10:55:35²Ä9949½g¦^À³
Besremi¥Ø«e¬ü°ê«OÀI±¡§Î¡G(¸ê®Æ­Y¦³»~¡A½Ð¥HÃĵØÃĤ½¥q¥¿¦¡¤½§i¬°·Ç)¡C

¤@¡BKaiser Permanente

BESREMI¡C

NOTE:µL¡C

wa.kaiserpermanente.org/static/pdf/public/formulary/largegroup-tier3-formulary.pdf

¤G¡BHealthPartners

BESREMI

LIMITS&RESTRICTIONS:PA

www.healthpartners.com/ucm/groups/public/@hp/@public/documents/documents/entry_218240.pdf

¤T¡BAnthem BlueCross

Besremi

NOTES&RESTRICTIONS: PA

client.formularynavigator.com/Search.aspx?siteCode=1227528522&targetScreen=3&drugBrandListBaseKey=besremi%2Bsubcutaneous%2Bsolution%2Bprefilled%2Bsyringe%2B500%2Bmcg%252fml&drugId=217171

¥|¡BHealth Alliance

BESREMI

NOTES:PA

www.healthalliance.org/documents/formulary/666/2022

¤­¡BBlueCross BlueShield

BESREMI

Additional Information: PA

fm.formularynavigator.com/FBO/68/BCBS_AZ_2022_Coinsurance_Member_.pdf

¤»¡BTUFTS HEALTH Plan

Besremi

Tier¡GNTM(New-to-Market)

Pharmacy Program¡GµL¡C

formularysearch.caremark.com/formularypdf/TuftsByTier_3.pdf

³Æµù¡G

PA(Prior Authorization):

You may need to get benefits approved before certain prescriptions can be filled.

·|­û:pete591410145259µoªí®É¶¡:2022/1/3 ¤U¤È 11:10:18²Ä9948½g¦^À³
ÃĵØÂåÃÄ

ÃĵØÃĨu¯f·sÃÄ ¯Ç¤J¬ü°ê³Ì¤j³sÂêÂå°|³Í·æÂåÀøµ¹¥I

money.udn.com/money/story/5613/6006945?from=edn_newestlist_rank

·|­û:pete591410145259µoªí®É¶¡:2022/1/3 ¤U¤È 10:51:28²Ä9947½g¦^À³
ÃĵØÃĨu¯f·sÃÄ ¯Ç¤J¬ü°ê³Ì¤j³sÂêÂå°|³Í·æÂåÀøµ¹¥I

ÃĵØÃÄ¡]6446¡^¤µ¡]3¡^¤é±ß¶¡«Å¥¬¡AºX¤U·sÃÄRopeginterferon alfa-2b¡]©ÎP1101¡A¥H¤U²ºÙRopeg¡^¯Ç¤J¬ü°ê³Ì¤j³sÂêÂå°|³Í·æÂåÀø¶°¹Îµ¹¥I¡C

ÃĵØÂåÃĪí¥Ü¡A³Í·æÂåÀø¶°¹Î¡]Kaiser Permanente¡^¬O¬ü°ê³Ì¤jªº°]¹Îªk¤H³sÂêÂå°|¡A¾Ö¦³39¶¡Âå°|¤Î700¦h¶¡ÂåÀø¾÷ºc¡B¶W¹L30¸U¦W­û¤u¡A¨ä¤¤Âå®v¶W¹L2¸U¦W¡AÅ@²z®v¶W¹L6¸U¤H¡C³Í·æÂåÀø¶°¹Î¦b¬ü°êªºÀç¹B¾î¸ó¤K­Ó¦{¡]¥]¬A¥[¦{¡BµØ²±¹y¦{¡B¶ø°Ç©£¦{¡B¬ìù©Ô¦h¦{¡B®L«Â¦i¦{¡B³ìªv¨È¦{¡B°¨¨½Äõ¦{¤Îºû¦N¥§¨È¦{¡^¥H¤ÎµØ²±¹y¯S°Ï¡A¦b¥þ¬ü¾Ö¦³¶W¹L1,200¸U¦W·|­û¡C³o¨Ç¦{¦b¬ü°êÄÝ©ó¬Û¹ï´I¸Î¥B¦Ñ¦~¤H¤f¶°¤¤ªº¦{¡A³Í·æÂåÀø¶°¹Î¦b³o´X­Ó­«­nªº¦{¾Ö¦³«D±`¤j¼vÅT¤O¡C

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2022/1/3 ¤U¤È 02:21:18²Ä9946½g¦^À³
zh.wikipedia.org/wiki/%E7%BE%8E%E5%9C%8B%E8%99%95%E6%96%B9%E8%97%A5%E5%83%B9%E6%A0%BC#%E5%AD%A4%E5%85%92%E8%97%A5

©t¨àÃÄ

ÃÄ«~¤½¥q¥i¬°·sÃÄ¡A¯S§O¬O©t¨àÃÄ¡]¬ü°ê¹ï³oºØÃĪº©w¸q¬O¼vÅT¤£¨ì200,000¦W¨u¨£¯e¯f±wªÌ¨Ï¥ÎªºÃĪ«¡^©w»ù¡A»ù®æ°ª¨ì¤@¯ë­Ó¤HµL¤O¤ä¥I¡A¦Ó¥Ñ«OÀI¤½¥q©Î¬F©²¨Ó§@¥I´Ú¤H¡C°ê·|³q¹Lªº¡m1983¦~©t¨àÃĪk®×¡n¡]ODA¡^¡A¥Øªº¬O¿EÀyÃļt¬ã¨s¨u¨£¯e¯f¡A¶}µoªvÀø¨Ò¦p«á¤Ñ©ÊA«¬¦å¤Í¯f©M½¦½è¥À²Ó­M½FªºÃÄ«~¡C¦bODA¥ßªk¤§«e¡AFDA¦@§å­ã34ºØ©t¨àÃÄ¡C¦bODA³q¹L¤§«á¡AFDA¦bÀH«áªº¤Q¦~¤¤§å­ã500¦hºØ©t¨àÃÄ¡C¦¨¥\¹ê²{¼W¥[©t¨àÃĪº¥Ø¼Ð¡C©t¨àÃĤ@¦~ªº¨Ï¥Î¶O¥Î¥i¯à°ª¹F40¸U¬ü¤¸¡C¨Æ¹êÃÒ©ú¡AÃbÂ_©t¨àÃĬOÃļt¬Û·í¦³§Q¥i¹Ïªºµ¦²¤¡C¨u¨£¯e¯fªº±wªÌ¼Æ¥Ø¤£¤j¡A¦]¦¹µL»Ý¦bÀç¾P¤W§ë¤J¤jµ§¸êª÷¡A±wªÌ¤Ö¦³¨ä¥L¿ï¾Ü¡C¦¹¥~¡A¤j¦h¼Æ©t¨àÃÄ¡]93¢H¡^³£¥Ñ«OÀI¤½¥q¤ä¥I¡C­±¹ï¤£Â_ªº§åµû¡AÃļtªº°ªºÞ¬°³oºØ°µªkÅGÅ@¡A«ü¥X¥Ñ©ó°ª¦¨¥»¡A¥L­Ì¤½¥q¤~¯à°÷¬°·¥¤Ö¼Æ»Ý­n³oºØÃĪ«ªº±wªÌ¥Í²£ÃÄ«~¡A¦ý¤j¦h¼Æ¿©±w¨u¨£¯e¯fªº±wªÌ´X¥G¬O¤£»Ý­n±µ¨ü¥ô¦óªvÀø¡C

±Mª`¦b©t¨àÃĪº¬ãµo¡A¦³®É¤]·|¥H¥¢±Ñ¦¬³õ¡C¨Ò¦p¡AAlipogene tiparvovec¡]°Ó«~¦WGlybera¡^¬O¥Î©óªvÀø¨u¨£ªº¯×³J¥Õ¯×酶¯Ê¥F¿ò¶Ç¯fªºªºÃĪ«¡Aª`®g¤@¦¸»Ý­nªá¶O100¸U¬ü¤¸¡A¦ý¥Ñ©ó»Ý¨D¤£¨¬¦Ó³Q¤U¬[¡C¦ý¬O¡A¦³«Ü¦h°w¹ï©t¨àÃĪ«¶}µoªº¹ê¨Ò¡AÃÒ©ú¹ïÃļt¨Ó»¡¬OÀò§Q»áÂתº¼Ò¦¡¡C¨Ò¦p¡A¨È¤O¥S»sÃÄ©ó2007¦~±À¥XEculizumab¡]°Ó«~¦WSoliris¡]µÎ¥ß·ç¡^¡^¡A³o¶µÃÄ«~¥Î©óªvÀø¨u¨£ªº¦å²G¯fÅÜ¡C¨C¦W±wªÌ¨Ï¥ÎSolirisªº¶O¥Î¨C¦~¬ù¬°41¸U¬ü¤¸¡A§Y¨Ï±wªÌ¥u¦³9,000¤H¡A2016¦~ªºÁ`¾P°âÃB¤]¥i¹F¨ì28»õ¬ü¤¸¡C

·|­û:¥ý¶i10000164µoªí®É¶¡:2022/1/3 ¤W¤È 10:59:47²Ä9945½g¦^À³
¬Ý©x¤j~ÀR«Ý¤½¥q¦p¦ó¿ì²z¡A§O«æ¡A»¡¤£©w°ª¼h¦ò¤ß¨Óªº¥Ñ¥þÅéªÑªF¼W¸ê»{ÁÊ¡A²q´ú·|¦b¹A¾ä¦~«e¤½¥¬§a
·|­û:¬Ý©x10141406µoªí®É¶¡:2022/1/3 ¤W¤È 09:38:33²Ä9944½g¦^À³
¤µ¦­¶^°±

¤½¥q«ç»ò¿ì²z¼W¸ê®×¡H¨p¶Ò¡H¥þÅéªÑªF¼W¸ê¡H

§Ú­ÌÀR«Ý¬Ý¤½¥q¾lÃB3¸U6¥a¦h±i¦p¦ó³B²z

°²³]ÁÙ¬O¥Î¨p¶Ò¤S¬O¦P¨º¤@²¼¤Hª«

¦b³ø½ÐÃÒºÞ·|¬d©ú¨º¨Ç¤H­û¬O§_¦³¹Ï§Q²{¶H¡H

·|­û:DHL10147526µoªí®É¶¡:2022/1/1 ¤U¤È 09:30:28²Ä9943½g¦^À³
ÃĵجO¦nªÑ²¼¡A

ªø´Á¦b³o¸Ì¯Ñ¯Ð³£ª¾¹D¥¦ªº¦n¡A

«Ü©¯¹B¦³³o¨Ç¦P¦n¤À¨É¸ê®Æ¡C

¯¬¤j®a¥¼¨Ó´X¦~³£¯à¤~´I¦Û¥Ñ¡C

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2022/1/1 ¤U¤È 05:48:32²Ä9942½g¦^À³
3 Reasons to Add McKesson (MCK) Stock to Your Portfolio

±N McKesson (MCK) ªÑ²¼²K¥[¨ì±zªº§ë¸ê²Õ¦Xªº 3 ­Ó²z¥Ñ

By Zacks Equity Research December 31, 2021

(¸`¿ý)

Strength in Biologics: Investors are optimistic about McKesson¡¦s robust Biologics business. Independent specialty pharmacy, Biologics by McKesson, has been making impressive progress of late. This month, the pharmacy was selected by PharmaEssentia USA Corporation as a specialty pharmacy provider of BESREMi (ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia vera.

¥Íª«»s¾¯ªºÀu¶Õ¡G§ë¸êªÌ¹ï McKesson ±j«lªº¥Íª«»s¾¯·~°È«ù¼ÖÆ[ºA«×¡C¿W¥ß±M·~ÃĩРBiologics by McKesson ³Ìªñ¨ú±o¤F¥O¤HÆf¥Øªº¶i®i¡C¥»¤ë¡A¸ÓÃĩгQ PharmaEssentia USA Corporation ¿ï¬° BESREMi¡]ropeginterferon alfa-2b-njft¡^ªº±M·~ÃĩШÑÀ³°Ó¡A¥Î©óªvÀø¦¨¤H¯u©Ê¬õ²Ó­M¼W¦h¯g¡C

www.entrepreneur.com/article/410999

·|­û:­¸¯T10148959µoªí®É¶¡:2022/1/1 ¤U¤È 03:17:40²Ä9941½g¦^À³
ÁÂÁ¤p¥¿¥¿¤j¤À¨É

¸ê®ÆÅã¥Ü¥Ñ©ó¬Ì±¡ FDA¥Ø«e¹ï©ó°ê¥~¬d¼t°ò¥»¤W¬O°±Â\ªº

ÃĵØÃįà¦b2021¦~¤´¯àÀòFDA­u¥~°ê¬d¼t¡A¨Ã¨ú±oÃÄÃÒ¡AÀ³¸Ó¬O¹ï­«¤j¯e¯f¤@½u¥Î·sÃĪº¯S§O«Ý¹J

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2022/1/1 ¤U¤È 01:45:15²Ä9940½g¦^À³
¡¯¡¯¸ê®Æ­Y¦³¤Þ­z¿ù»~¡A½Ð¥HÃĵØÃĤ½¥q¥¿¦¡¤½§i¬°·Ç¡C

¡¯¡¯½g´T¹Lªø¡A½Ð¿ï¾Ü¬O§_¾\Ū¡A¥H§K®ö¶OÄ_¶Q®É¶¡¡C

¡¯¡¯¤U­z¸ê®Æ¡A¶È¨Ñ°Ñ¦Ò¡A­YµL°Ñ¦Ò»ù­È©Î½×­z¿ù»~¡A½Ð·í¯º¸Ü¤@1«h¡C

ÁÂÁÂ!!

¡¯¡¯°ÝÃD¡G·s»D¸ê®Æ¦^ÅU

¤@¡BÃĵØÃĦ۱q2021¦~11¤ë13¤é¨ú±o¬ü°êFDAÃÄÃÒ«á¡A¬ü°êPVº¯³z²v¸Û¦p

¤½¥q©Ò¨¥¡APV±wªÌªº«OÀIÂл\°·¥þ¡AP1101®Ö­ã²Ä¤@¤Ñ¶}©l´N¥i¥H«OÀIµ¹¥I¡AÃĵØÃĹw­p¦b6­Ó¤ë¤º¦³80%ªº«OÀIÂл\²v¡C¥B¥iªvÀø¹O8¸U¦W¯f±w¡C¼ÖÆ[ªº¸Ü¥i¹F10¸U¤H¡C

(°ÝÃD¡G6­Ó¤ë¤º¦³80%ªº«OÀIÂл\²v¡A¯f±w¼Æ¬O´X¤H?¡F¥BªvÀø¹O8¸U¦W¯f±w¡A¬ù´X¦~¹F¦¨?¡F¼ÖÆ[ªº¸Ü¥i¹F10¸U¤H¡A´X¦~¹F¦¨?)

¤G¡BÃĵØÃĬݦn¡A¸Ó·sÃĬü°ê FDA ®Ö­ãªº¥é³æ¨Ï¥Î½d³ò¸û¼Ú·ù¼s¡A©Ò¦³¯u©Ê¬õ¦å²y¼W¦h¯g (PV) ¦¨¤H¯f±w§¡¥i¨Ï¥Î¡A¥B»ù®æ¤ñ³Ì¤jÄvª§ÃÄ«~ jakafi §ó¨ãÄvª§¤O¡Aº¯³z²v±NÀu©óÄvª§¹ï¤â¡C¬ü°êÃļt Incyte ¶}µoªº jakafi¡A¸ÓÃÄ«~¬° PV ¤G½u¥ÎÃÄ¡A¤W¥«­º¦~ªvÀø 800 ¦W¯f±w¡A¤W¥««á²Ä 7 ¦~¬ü°ê¾P°âÃB¹F¨ì 10 »õ¬ü¤¸¡A¨ÃªvÀø¶W¹L¸U¤H¡AÃĵØÃÄ»{¬°¡ABESREMi ©ó¬ü°ê¤W¥«­º¦~ªº¯f±w¼Æ¡A±N¶W¹L jakafi¡C

(°ÝÃD¡G²Ä¤@¦~¯f±w¼Æ¡A¥i¹F´X¤H?¡F¦ó®É¥i¹F10 »õ¬ü¤¸?)

¤T¡B¥H¤W°ÝÃD¡A¥i¯à¦³¿àÃĵØÃĬü°ê¤½¥q¹Î¶¤§V¤O¡A¾¨¦­§V¤O¹F¦¨¡C

(¬ü°ê·~°ÈÁ`¸g²z±ö¹p­}«ä•°Ò¹ç (Meredith Manning) ²¦·~©óªÛ¥[­ô¤j¾Ç¥¬´µ°Ó¾Ç°|¡A¾Ö¦³¤G¤Q¦~¦b¬ü°ê³»¯Å»sÃĤ½¥q¾á¥ô²£«~¾Ô²¤±M®aªº¸gÅç¡C¦o­t³d¼Æ¤Q»õ¬ü¤¸ªº²£«~½u¡A¨Ã´¿¦b¤K­Ó¤ë¤º¦¨¥\¹ê²{¤@¶µ·sÃĸ겣ªº¾P°âÃB¹F 10 »õ¬ü¤¸¡C)

¡¯¡¯°ÝÃD¡GBesremi¬ü°êº¯³z²v?

­Ó¤H¹ï¬ü°êº¯³z²v«ù¼ÖÆ[ºA«×¡A¤£¹L¶È¬O­Ó¤H«H¥õ»PÁr´ú¡A¨ÃµL¥ô¦ó§â

´¤¡A¤U¦C½×­z¡A¶È¨Ñ°Ñ¦Ò¡A­YµL°Ñ¦Ò»ù­È©Î½×­z¿ù»~¡A½Ð·í¯º¸Ü¤@«h:

¤@¡B±q¬ÛÃöMPNªÀ¸sºô¯¸¡APV¯f±w¨Ï¥ÎBesremi·NÄ@°ª¡A«OÀI°ÝÃD¤´¦b§V¤O¤¤©Î³°ÄòÀò±o¸Ñ¨M¡C¸`¿ýªñ¤G¤ÑPV¯f±wªº½Í¸Ü¡G

(±©MPN¬ÛÃöªÀ¸sºô¯¸¥À¸sÅ鼯¶È¬O­Ó®×¡A¬O§_¦³¥Nªí©Ê?)

(¤@)Wow! I hope I can get my insurance to approve it! But I will still have to come up with the first $10,000 for my yearly deductible.

«z¡I§Ú§Æ±æ§Ú¯à±o¨ì§Úªº«OÀI§å­ã¡I¦ý¬O§Ú¤´µM»Ý­n¬°§Úªº¦~«×§K½ßÃB®³¥X²Ä¤@µ§ 10,000 ¬ü¤¸¡C

(¤G)My insurance approved Besremi for PV. (I know not everyone has been able to get it approved and I hope they can.)

§Úªº«OÀI¤½¥q§å­ã Besremi ¥Î©ó PV¡C¡]§Úª¾¹D¤£¬O¨C­Ó¤H³£¯àÀò±o§å­ã¡A§Ú§Æ±æ¥L­Ì¥i¥H¡C¡^

(¤T)PAN Foundation has approved Besremi¡Cjust had to share that my grant was accepted and will be starting BESREMI in January! My oncologist is as thrilled as me!

PAN °òª÷·|¤w§å­ã Besremi¡C­è­è¤À¨É§Úªº¸ê§U¤w³Q±µ¨ü¡A¨Ã±N¦b 1 ¤ë¥÷±Ò°Ê BESREMI¡I§Úªº¸~½F¬ìÂå¥Í©M§Ú¤@¼Ë¿E°Ê¡I

So PAN is now covering Besremi?

©Ò¥HPAN²{¦bÂл\Besremi¡H

Yes.

¬Oªº¡C

(¥|)My Besremi was approved and being delivered next week. I¡¦m so nervous! Has anyone else starting it?

§Úªº Besremi ¤wÀò§å¨Ã©ó¤U¶g¥æ¥I¡C§Ú¦nºò±i¡I¦³¨ä¥L¤H¶}©l¶Ü¡H

(¤­)Mine¡¦s still stuck at $6k per month. I need to work quickly with my hematologist to get the price down considerably before I can access it. Good luck to you!!

§Úªº¤´µM°±¯d¦b¨C¤ë 6,000 ¬ü¤¸¡C§Ú»Ý­n»P§Úªº¦å²G¬ìÂå¥Í¨³³t¦X§@¡A¦b§ÚÀò±o¥¦¤§«e¤j´T­°§C»ù®æ¡C¯¬§A¦n¹B ¡I¡I

(¤»)I¡¦m still waiting¡K good luck!¡C

§ÚÁÙ¦bµ¥¡K¡K¯¬§A¦n¹B¡I

(¤C)Hoping to have that myself soon.

§Æ±æ¦Û¤v¦­¤é¾Ö¦³¡C

(¤K)I just got the phone call I¡¦m being switched

§Ú­è±µ¨ì¹q¸Ü§Ú¥i¥HÂà´«¤F¡C

(¤E)I¡¦m hoping to get it soon.

§Ú§Æ±æºÉ§Ö±o¨ì¥¦¡C

¤G¡BBesremi V.S. Pegasys®

(¤@) Pegasys®¬ü°ê¦ó®É°±²£©Î°±¤î¨ÑÀ³¡A­Ó¤H¬dµL½T¤Á¤é´Á¡A±©Pegasys®§Y©Ò¿×off label ¨Ï¥Î¡AÂå¥Í¥²¶·¥ý¼x±o¯f¤H©MÂå«Oªº¦P·N¤~¯à¤UÃÄ¡A¦P®ÉÂå¥Í¦Û¤v¤]¥²¶·©Ó¾á¦h¤@¼hªº¹D¼w©MÂåÀø³d¥ô¡C¦P®É¡A¨Ã¥B¦b¬ü°ê¡AÂå¥Í§A毎¤Ñ¹ï¯f¤H©Ò»¡¨C¥y¸Ü¡A©Ò°µªº¨C¥ó¨Æ¡A³£¥²¶·°µ¦n¦³¤@¤Ñ¦bªk®x¤W¬°¦Û¤vªº¦æ¬°©M«áªGÅGÅ@ªº·Ç³Æ¡C¬ü°ê¦³¥@¬É¤W³Ì¦hªº«ß®v¡A¥L­ÌµL¤Õ¤£¤J¡A¬JÄ@·N¬°´I¤H¥´©x¥q¡A¤]¼Ö·N¬°½a¤H¥´©x¥q¡C¥I¤£°_«ß®v¶O¨SÃö«Y¡A©x¥q¿é¤F¤£­n¿ú¡A©x¥qŤF¦A¤À¦¨¡CÂå¥Í¥i¿×À£¤O¤j¡C

(¤G) Ruben Mesa©ó10 facts MPN patients need to know about FDA approval of Ropegylated interferon alpha2b (Besremi)¼v¤ù°ÝÃD8´£¤Î¡A­Y¨Ï¥Î¥½ÀòFDA®Ö­ãªº¤zÂZ¯ÀªvÀø®ÄªG¤£¨Î¡A±j¯P¦Ò¼{¡ustronger consideration¡vÂà´«¦Ü(Besremi)¡CPegasys®¨ÃµL¨ú±oFDAÃÄÃÒ¡AÂå¥Í¨Ï¥Î¤zÂZ¯ÀªvÀøPV­º¿ï¡AÀ³¬O¦³ÃÄÃÒBesremi¡ABesremi¨ú¥NPegasys®¬O¦­±ßªº°ÝÃD¡C

¤T¡BBesremi V.S. jakafi

(¤@)Besremi »Pjakafi»ù®æ¬Û¦ü¡A±©Besremi¬O¤@½u¥ÎÃÄ¡Bjakafi¬O¤G½u¥Î

ÃÄ¡ABesremi¦ÛµM¨ã¦³§¹¥þÄvª§¤O¡C

(¤G)ªp¥B¡AFDA«ü¥XBesremi¦b¨Ï¥Î¤@¦~«á¥i¥H´î¤Ö¦h¾lªº¦å²Ó­M¨Ã«O«ù¥¿±`

¤ô¥­¦Ü¤Ö¤@¦~¡A¨º»òµ¹ÃÄÀW²v¥i¯à·|´î¤Ö¨ì¨C¥|­Ó¬P´Á¤@¦¸¡A²Ä2¦~°_¨C¤ë1

°w¡A¬ù13°w¡A»ù®æ¦ÛµM´î¥b¡A¥B¦³ªv¡¥i¯à¡A´N«OÀI¤½¥q¸gÀÙ¦¨¥»®Ä¯q¦Ò¶q¡A

·íµM¿ï¾ÜBesremi¡C

¥|¡BBesremi V.S. HU

°Ñ·Ó¡G(QIC¼e¶q°ê»Ú»PCEO¹ï½Í²Ä¤G¤Q¤­´Á¡GMeredith Manning¤k¤h)

Q¡G¥Ø«e HU ³Q¼sªx¥Î©óªvÀø¤@½u PV¡A¨Ã¥B¤ñ BESREMi® «K©y¡C¬°¤°»ò«OÀI¤½¥q­n¤ä«ù BESREMi®¡H

M¡GÁöµM¦¨¥»¬O¤@­Ó­«­n°Ñ¼Æ¡A¦ý«OÀI¤½¥q¤]©ú¥ÕÀ³¸Ó©Ó«O¨ã¦³©ú½TÁ{§É¯q³Bªº²£«~¡C¥I´Ú¤H§Æ±æ½T«O¥L­Ì§ë¸êªº²£«~¹ï¥L­Ìªº±wªÌ¸sÅ馳¯q¡C§Ú­Ìªº¤u§@¬O¦V¥I´Ú¤H¶Ç¹F BESREMi® ±N¬°¥L­Ìªº±wªÌ¸sÅé±a¨Ó¤°»ò¦n³B¡C³o¬O¤@ºØªø´Á¯e¯f¡A¦]¦¹¥I´Ú¤H§óÄ@·N¬°¥i¥Hªø´Á±±¨î¯e¯fªº²£«~¥I´Ú¡CHU ¹ê»Ú¤W¤£¬O FDA §å­ãªº PV ÃĪ«¡AÁöµM¥¦«Ü«K©y¡A¦ý±q²{¹ê¥@¬Éªº¼Æ¾Ú¤¤¥i¥H²M·¡¦a¬Ý¥X¡A±wªÌªº¦å²Ó­M­p¼Æ¤£¨ü±±¨î¡C§Y¨Ï¥¦«Ü«K©y¡A¦pªG¥¦¤£°_§@¥Î¡A¬°¤°»ò¦³¤H­n¥I¶O©O¡H

¤­¡Bºî¤W¡GBesremi¦³¥i¯à³q¦YPV¥«³õ¡A­È±o´Á«Ý¡A¦ý§Æ±æ¾¨¦­¹F¦¨¡C¦P®É¡AªÑ»ù¾¨¦­¹F¨ì¥ý¶i¤j¤§«e¼ÐÃDªº¥Ø¼Ð»ù¡A¦­¤é¹F¦¨°]°È¦Û¥Ñ¡C

¡¯¡¯³Æµù¡G

·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2021/12/31 ¤U¤È 02:50:20²Ä9939½g¦^À³
3 Top Growth Stocks to Consider Buying in January

¤¸¤ë¥÷¦Ò¼{ÁʶRªº 3 ¤äº¦¶Õ³Ì¨ÎªºªÑ²¼

By Priyanka Mandal

Dec 29, 2021

(ºK¿ý)

ÁöµM³q¼ê¤W¤É©M omicron «aª¬¯f¬rÅܺتº«ùÄò¶Ç¼½¡A¹w­p·|Åý§ë¸êªÌ·P¨ì¾á¼~¡A¦ý°²¤é¾P°â³Ð¬ö¿ýªº¼Wªø©M±j«lªº®ø¶OªÌ«H¤ßÀ³¸Ó·|¤ä¼µ°ò·Ç«ü¼Æ¡C¦]¦¹¡A¾Ö¦³Ã­°·¼WªøÄݩʪº S&P Global (SPGI)¡BSynopsys (SNPS) ©M Veeva Systems (VEEV) ²{¦b¥i¯à¬O²z·Qªº§ë¸ê¡C

Veeva Systems Inc. ( VEEV -Àò±oµû¯Å)

VEEV ¦¨¥ß©ó 2007 ¦~¡A¬°¥_¬ü¡B¼Ú¬w¡B¨È¤Ó¦a°Ï¡B¤¤ªF¡B«D¬w©M©Ô¤B¬ü¬wªº¥Í©R¬ì¾Ç¦æ·~´£¨Ñ°ò©ó¶³ªº³n¥ó¡C¸Ó¤½¥qªº¸Ñ¨M¤è®×¥]¬A¶³³n¥ó¡B¼Æ¾Ú©M·~°È¿Ô¸ß¡CVEEV ¬°¥Í©R¬ì¾Ç¦æ·~´£¨Ñªº¦æ·~¶³¸Ñ¨M¤è®×¤À¬°¨â­Ó²£«~»â°ì¡GVeeva Commercial Cloud ©M Veeva Vault¡C

¥»¤ë¡A¥Íª«§Þ³N¤½¥q PharmaEssentia ±Ä¥Î VEEV ªº¼Æ¾Ú¤ª¨Ó¤ä«ù BESREMi ªº±À¥X¡A³o¬O¤@ºØªvÀø¨u¨£¦åÀù¯u©Ê¬õ²Ó­M¼W¦h¯g (PV) ªº·sÀøªk¡C­É§U¼Æ¾Ú¤ª¡AVEEV À³³q¹L¦hºØ°Ó·~¤ÀªR©M¹BÀç¤u§@¬yµ{¤ä«ù PharmaEssentia¡A¥H«K¤½¥q¥i¥H§ó¦n¦a´N¨ä­«­nªº·sªvÀø¤è®×¹ïÃöÁä HCP ¶i¦æ±Ð¨|¡C

stocknews.com/news/spgi-snps-veev-3-top-growth-stocks-to-consider-buying-in-january/

·|­û:¬Ý©x10141406µoªí®É¶¡:2021/12/29 ¤W¤È 11:28:15²Ä9938½g¦^À³
§Ú¤]¬O¦]¥ý¶i¤j¹ïÃĵز£«~ªºÁA¸Ñ»P«H¤ß¤~¤ä«ù¨ì²{¦b

µM¦Ó¹ï³o2¦¸¡]«e´X¦¸¤]¬O¡^¨p¶Ò¹ï¶H¨Ã«D§¹¥þ¬O¤½¥q¬£ ¦³¨Ç¤H¨Ã¤£¬O¡I

¾Ú§ÚªB¤ÍÁA¸Ñ§iª¾±¡ªp¬O³o¨Ç«D¤½¥q¬£¯S©w¤H¥u¬O¦b¥_³¡¬Y¤s°Ï­Ñ¼Ö³¡¦¨­ûªÑªF¦Ó¤w

¦p¦¹³o¯ë¨p¤ß¾Þ§@¯àÅý¤H¤£·P¨ì¿ò¾Ñ¶Ü¡H

·|­û:¥ý¶i10000164µoªí®É¶¡:2021/12/29 ¤W¤È 10:15:35²Ä9937½g¦^À³
¹ï©óÃĵØÃĨp¶Ò®×§ä©T©w¯S©w¤H¡A¹Ï§Q©~¦h§@·~¬yµ{¤]¤j·§³£¤F¸Ñ¡A»·¤ñ§A­Ì·Q¹³¤¤ªº¦h¡A¤£·QÁ¿¤Ó¦h¤Ó©ú¥Õ

²³æ»¡¨p¶Ò®×§ä­ì¨º¨Ç©T©w¯S©w¤H¡A¹ïªÑ»ù¼vÅT«Ü¤j¡A¸T¤î¦A¨p¶ÒºûÅ@¥þÅé¤pªÑªFÅv¯q´N¹ï¤F

·|­û:¥ý¶i10000164µoªí®É¶¡:2021/12/29 ¤W¤È 10:00:34²Ä9936½g¦^À³
¹ï©óÃĵØÃĨp¶Ò®×§ä©T©w¯S©w¤H¡A¹Ï§Q©~¦h§@·~¬yµ{¤]¤j·§³£¤F¸Ñ¡A»·¤ñ§A­Ì·Q¹³¤¤ªº¦h¡A¤£·QÁ¿¤Ó¦h¤Ó©ú¥Õ

²³æ»¡¨p¶Ò®×§ä­ì¨º¨Ç©T©w¯S©w¤H¡A¹ïªÑ»ù¼vÅT«Ü¤j¡A¸T¤î¦A¨p¶ÒºûÅ@¥þÅé¤pªÑÅv¯q´N¹ï¤F

·|­û:YiHong10143518µoªí®É¶¡:2021/12/29 ¤W¤È 09:12:57²Ä9935½g¦^À³
¹ï©ó¥ý¶i»P¬Ý©x¤j¨p¶Òªº¬Ýªk¡A¤p§Ì·Qµoªí¤@¤U¦Û¤vªº¬Ýªk¡C

¦Û¤v¤»¦~«e¶}©l§ë¸ê¡A¤]¬O¬ÝµÛ¥ý¶i¤j¸ê°T»P¤ä«ù¨«¹L¨Ó¡Aª¾¹D¥ý¶i¤j¬O¬°¤F§Ú­Ì³o¨Ç¦ÑªÑªF³]·Q¡C

¦ý¹ï©ó³o¦¸¨p¶Ò¨ä¹êı±oÁÙ¥i¥H±µ¨ü¡A­ì¦]¦³¤TÂI:

1. ¦Û¤v»P®a¤H¨ä¹ê¦b¦­´Á70 - 209´Á¶¡³£¦³¶R¤J¡A§Ú­Ì³oºØ´²¤á¥i¥H¶R­Ó¤@¤G¤Q±i¸êª÷¤]®t¤£¦h¡A´N³s¤§«eªº¼W¸ê802ªÑ¤]¬O¬Ù¦Y»ü¥Î´ê¥X¨Óªº¡A¥»¨­¨S¦³¤°»ò¦h¾l¸êª÷¡A¦]¦¹¥H²{¦bªºªÑ»ù¼W¸ê177©ÎªÌ235»ù®æ¹ï§Ú­Ì¨Ó»¡°Ñ¥[·NÄ@¤£°ª¡A¦¹¥~¤½¶}¼W¸ê¬O¤£¬O©Òªáªº®É¶¡·|¤ñ¸ûªø¡A¥Ø«e­Ó¤H·Pı¤½¥q»Ý­n¤@µ§¸êª÷¬O¥¼¨ÓºÉ§Ö¶i¤J¤U­Ó¶¥¬q¡A¨Ò¦p:¸Ñ°£¥þÃB¥æ³Î...¤§Ãþ(±À´ú)¡C

2. ¨p¶Ò¹ï¶HÁöµM¤j³¡¤À³£¬O¤½¥q¤º³¡¤H¡A¹Ï§Q¨ì¤½¥q¬£¤H­û¡A¦ý¦³¨Ç°Q½×ª©¦³¤@­Ó»¡ªk¦Û¤v¥»¨­Ä±±o¥i¯à©Ê¬Û·í°ª¡A¬°¤F¾d©T¤½¥q¬£ªºªÑÅv¡C¦Û¤v«á¨Ó·Q¤F¤@¤U¡A¦pªG³o¤­¸U±i¨p¶Ò³£¬Oµ¹¥~¤H¡A©¹«áÁÙ¦³¬F©²ªÑ²¼·|ÄÀ¥X¬ù¨â¤T¸U±i¡A³o¼Ë¤½¥q¬£ªº¤H­ûªÑÅv¥²µM·|¨ü¨ì¤@©wªº«Â¯Ù¡A¤@­Ó¤½¥qªº¤j¤áªÑªF³£Ä@·N¤ä«ù¡A¤Ï¦Ó¹ï§Ú­Ì¨Ó»¡¬O¤@ºØ«ü¼Ð¡A½T©w¤½¥q¤w¸g©¹§ó¦nªº¤è¦Vµo®i¡C

3. ²Ä¤TÂI¬O°w¹ï¬O§_¦³Â´«·sªº¶ûºÃ¡A­Ó¤H¦³°µ¤F¤@¨ÇÄw½X¤ÀªR¡A²Ä¤@¦¸¨p¶Ò®Éªº½T¦³Â´«·sªº¶ûºÃ¡A¦ý²Ä¤G¦¸¬Ý¨ìªº²{¶H¤Ï¦Ó¬O§l¦¬¥~¸êªºÄw½X¡A¦Û¤vªº¤ÀªR¤W¨ÃµL´«·sªº¼x¥ü»P²Ä¤GÂI©IÀ³¡C

¥H¤W¤TÂI¬O§Ú³o¨â­Ó¤ë¬Ý¤F³\¦h¸ê°T»P¦Û¤vªº¤@¨Ç¤ÀªR±o¨ìªº¤ß±o¡C

¦³¤°»ò¤£¦Pªº¬Ýªk³£Åwªï´£¥X¡C

·|­û:§ë¸êªÌ10148182µoªí®É¶¡:2021/12/29 ¤W¤È 09:02:43²Ä9934½g¦^À³
¤jªÑªF.¬F©²..°êµo·|- 22,066±i... 8.36%

³£¦P·N..ÃÒºÞ·|·|¬d¶Ü

¤½¶}¦VªÑªF¼W¸ê...°êµo·|©ñ±ó..¬¢¯S©w¤H

µ²ªG¤@¼Ë

¦n³B..¨p¶Ò..º¡¤T¦~«á©l±o¦Û¥ÑÂàÅý

¤T¦~¥«³õ...Äw½X¤£¼W¥[

¨p¶Ò..²Ä1¦¸177¤¸..²Ä2¦¸...235¤¸

¥Nªí¤jªÑªF..¹ïÃĵØÃĪº«á¶Õ...ªø¦h¬Ýªk

¦@«j¤§

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2021/12/29 ¤W¤È 08:44:03²Ä9933½g¦^À³
¦³Ãö¨p¶Ò®×¡A­Ó¤H·M¨£¡A¬O§_¥i¥H±q¦³§U©óªÑ»ù¤Wº¦¡A±j¤Æ¥«³õ§ë¸ê¤H«H¤ß»P°l»ù·NÄ@¬°³Ì¤j¦Ò¶q­ì«h¡G

¦pÁÞÁp(4168)2013¦~8¤ë«Å¥¬¡AÂǥѨp¶Ò¤Þ¶i¤é¥»¤j¶ï»sÃݵ¬°µ¦²¤§ë¸ê¤H¡A¤j¶ï»sÃħë¤J2.76»õ¤¸¡F¥x±d¥Í(6589)2021¦~10¤ë¨p¶Ò®×50»õ¤¸¡A¥Ñ³¢¥x»Ê¥D¾Éªº¥x±d¥Í¨p¶Ò§ë¸ê®×¡A¤À§O¥HÂE®üºë±K¡B¥ÃÄָꥻ±±ªÑ¤Î³¢¥x»Ê­Ó¤H§ë¸êªºèbºû¤½¥q¤JªÑ¡C¤W­z2¥ó¨p¶Ò®×¡A¬Ò¹ï·í®É¤½¥qªÑ»ù³y¦¨¤Wº¦¡A±j¤Æ¥«³õ§ë¸ê¤H«H¤ß»P°l»ù·NÄ@¡C

¦]¦¹¡AÃĵØÃĤ½¥q­Y­nÄ~Äò¿ì²z¨p¶Ò®×¡A¬O§_À³Á×§K§ä­ì¦³ªÑªF°Ñ»P¨p¶Ò¡A¦Ó³y¦¨¥«³õ¦³¡u½æ¦ÑªÑ¡A´«·sªÑ¡v¼ç¦b½æÀ£¡AªÑ»ù¤£©ö¤Wº¦¡A¬Æ¦Ü¹Ï§Q¯S©wªÑªF¡A¦³¹HªÑªF¥­µ¥­ì«h¤§ºÃ¼{¡C

«ØÄ³¨p¶Ò®×¡AÀ³¤Þ¶i¡uµ¦²¤§ë¸ê¤H¡v¡A¥[±j¦X§@Ãö«Y¡F¦P®É¡A¯à¤Þ°_¥~¸ê¾÷ºc°ª«×§ë¸ê·NÄ@¡A¦p¤Þ¶i»PÃĵØÃĤ½¥q¦³·~°ÈÃö«Yªº¬ü°ê¤½¥q¡G

¤@¡BOnco360 ®¸~½FÃĩСG(¬ü°ê³Ì¤jªº¿W¥ß¸~½FÃÄ©Ð)

¤G¡BMcKesson Corporation(MCK)(¥_¬ü³Ì¤jÂåÃħåµo°Ó)¡C(ªÑ»ù246¤¸)

¤T¡BVeeva systems(VEEV)¡C(Veeva ¬O³Ð·s©Êªº¶³³n¥ó¤½¥q¡AÀ°§U 1,000 ¦h®a¥Í©R¬ì¾Ç¤½¥q§ó§Ö¦a¬°±wªÌ´£¨Ñ·sÃÄ©M·sÀøªk¡C)(ªÑ»ù258¤¸)

¥H¤W²L¨£¡A¤£ª¾¬O§_¥i¦æ?­Y¤£¥i¦æ¡A½Ð·í¯º¸Ü¤@«h!ÁÂÁ¡C

·|­û:¤p¥¿¥¿10142326µoªí®É¶¡:2021/12/29 ¤W¤È 07:48:40²Ä9932½g¦^À³
¸ê®Æ¨Ó·½¡Ghealthunlocked.com/mpnvoice/posts/private/147344831/besremi

Typically MPN specialists are experienced at handling the insurance appeal process. This should not have to fall on the shoulders of the patient. I have been to 3 different specialists over the past 4 years and they were all able to appeal and very quickly resolve any issue with obtaining my Pegasys. This was with private insurers however, and I understand medicaid/medicare is another matter. With FDA approval for Besremi I¡¦m not sure what grounds any of them would have to deny it on, unless it¡¦s just too soon and their documentation hasn¡¦t been updated or something. Due to life circumstances I am temporarily on Medicaid and my specialist told me that they can start prescribing Besremi as of today actually. I¡¦ll try and post back what my experience is with that. My next appt with the specialist is next week.

³q±`¡AMPN ±M¬ìÂå¥Í¦b³B²z«OÀI¤W¶D¹Lµ{¤è­±¸gÅçÂ×´I¡C³o¤£À³¸Ó¸¨¦b±wªÌªºªÓ¤W¡C¦b¹L¥hªº 4 ¦~¸Ì¡A§Ú¸g¾ú¹L 3 ¦ì¤£¦Pªº±M®a¡A¥L­Ì³£¯à°÷¤W¶D¨Ã«Ü§Ö¸Ñ¨M¤FÀò±o§Úªº Pegasys ªº¥ô¦ó°ÝÃD¡CµM¦Ó¡A³o¬O»P¨p¤H«OÀI¤½¥q¦X§@ªº¡A§Úª¾¹DÂåÀø¸É§U/ÂåÀø«OÀI¬O¥t¤@¦^¨Æ¡CÀHµÛ FDA ¹ï Besremi ªº§å­ã¡A§Ú¤£½T©w¥L­Ì¤¤ªº¥ô¦ó¤@­Ó¤H¦³¤°»ò²z¥Ñ¥²¶·§_¨M¥¦¡A°£«D¥¦¤Ó¦­¤F¡A©Î¬O¥L­Ìªº¤å¥óÁÙ¨S¦³§ó·s¤Î¦³¨ä¥L°ÝÃD¡C¥Ñ©ó¥Í¬¡±¡ªp¡A§Ú¼È®É±µ¨ü¤FÂåÀø¸É§U¡A§Úªº±M¬ìÂå¥Í§i¶D§Ú¡A¥L­Ì¹ê»Ú¤W¥i¥H±q¤µ¤Ñ¶}©l¶}¥X Besremi ³B¤è¡C§Ú·|¸ÕµÛµo¥¬§Úªº¸gÅç¡C§Ú»P±M¬ìÂå¥Í¤U¦¸ªº¬ù·|¬O¦b¤U©P¡C

·|­û:¥ý¶i10000164µoªí®É¶¡:2021/12/28 ¤U¤È 09:16:10²Ä9931½g¦^À³
¬Ý©x¤j§â¨p¶Ò®×¹Ï§Q¯S©w¤H»¡ªº«Ü¸Ô²Ó

¨Ò¦p:¤½¥q­n¦b1¤ë23¤é¦Ü1¤ë29¤éú´Ú¡A¨º»ò¨p¶Ò¹ï¶H¤Î±i¼Æ¦b1¤ë12¤é«e«á¤w½T©w

¨p¶Ò¤H¡u¼ôÃÑ­ìªÑªF¡v¦¬³qª¾«á¡A¥þ³¡ªº¯S©w¤H¶}©l¤j½æ¤â¤W«ùªÑ¡A¶i¦æÀ£»ù~1.¥i¥H½æ¨ì°ª»ù2.À£§CªÑ»ù«á¥´¤K§é¤S¥i¥H¼W¨ì³Ì§CªºªÑ»ù

¤@Á|¨â±oªº¤âªk¡A§|±þ­ì¥»ªÑªFÅv¯q¡A¯S©w¤H¨Ó¦^ì§Q®t»ù³Ì¤Ö120¤¸¥H¤W¡A¥»¤H´£«e¹w§iªñ´ÁÁÙ·|¦³²Ä¤T¦¸¨p¶Ò¡A¦]¾lÃB±i¼ÆÁÙ¦³3¸U6¥a¦h±i

ÃĵØÃĤ½§iú´Ú¤é´Á·í¤Ñ¡A©¹«e¬Ý¤Q¤ÑªºªÑ»ù¥²©w¨«¶^¡A¥L­Ì·Q¼W§C»ù®æ¥²©w­n¤j½æÀ£»ù¡A©Ò¥H¤pªÑªF­Ì­n¥h§Üij¡AÃĵØÃĤ£­n¤@¦Ó¦A¤T¨p¶Ò

­nµ¹¥þÅé§ë¸ê«ù¦³ÃĵØÃĪºªÑªFÀ³¦³ªºÅv¯q

·|­û:¬Ý©x10141406µoªí®É¶¡:2021/12/28 ¤U¤È 06:02:19²Ä9930½g¦^À³
Æg¦¨¥ý¶i¤j»¡ªk ¦bªÑ¥«¸Ì·í±þ¤â©Î­´µæ³£¥i¯à

¥D­n¬O¤½¥­¥¿¸q »¡¤F¦h¦¸¦³«ÜÃøÀ´¶Ü

ÁÙ¬O¼Ö¦b¨ä¤¤

·|­û:¥ý¶i10000164µoªí®É¶¡:2021/12/28 ¤U¤È 05:22:20²Ä9929½g¦^À³
­Y¬O¤½¥i¦³¸êª÷¯Ê¤f´£«e¤½¶}¦VªÑªF¼W¸ê¡A¬°¤°»ò¤£»°§Ö¶i¦æ¡A¹³¤W¦¸90¤¸¨p¶Ò®×¤@¼Ë¡A

¨p¶Ò¤F¤G~¤T¦¸³Ì«á¤@¦¸¤~¥Ñ¥þÅéªÑªF¼W¸ê·í®É»{ÁÊ»ù¬O90¤¸¤W¤U¡A¦A»¡¤F~ÃĵØÃijo¦¸5¸U±i

¬O¤£¬O¹³¤W¦¸¤@¼Ë¡Aµ¹¯S©w¤H3~4¦¸¨p¶Ò«á¡A³Ì«á¤@¦¸¤~¥þ³¡ªÑªF¼W¸ê©O¡H³o¦¸5¸U±i¨p¶Ò²Ä¤@

¦¸11¤ë23¤éú´Ú¦Ü11¤ë©³¡B²Ä¤G¦¸12¤ë23¤éú´Ú¦Ü¤ë©³¡A¨º»ò¦X²z·Q¹³1¤ë23¤é¤S¨Ó¤@¦¸¡H

¤@­Ó¨p¶Ò¤]·d´X­Ó¤ë¡A¸ò¤½¶}¼W¸ê¨ì©³®É¶¡®t¦h¤Ö¡H

·|­û:¤pÃC10147871µoªí®É¶¡:2021/12/28 ¤U¤È 04:53:41²Ä9928½g¦^À³
¨p¶Ò©Î²{¼W¥u­n¯à¦b¦³®Ä²vªº®É¶¡¤º¨ú±o¤½¥qªº¸êª÷»Ý¨D §Ú³£ÃÙ¦¨¡C ¦ý²{ª÷¼W¸ê »Ý­n¸g¹LÂd¶Rªº ¦Ó¥B§@·~®É¶¡­n´X­Ó¤ë¡C À³¸Ó®É¶¡¤W¨Ó¤£«æ¡C ©Ò¥H§Ú¿ï¾Ü¬Û«H¤½¥qªº¦w±Æ¡C
·|­û:¥ý¶i10000164µoªí®É¶¡:2021/12/28 ¤U¤È 04:39:57²Ä9927½g¦^À³
ÃĵØÃĦ^¨ìÀ³¦³ªº»ù­È¡A¬OªÑªFªø´Á°í«ù«ù¦³ªºªG¹ê¡A¤]¦]³q¹L¤FFDAªºÃÄÃҪѻù¤~¦³ªí²{¡A¸ò¨p¶Ò®×¬O¤G½X¨Æ¡A¤£¯à²V¬°¤@½Í
·|­û:andytom10148211µoªí®É¶¡:2021/12/28 ¤U¤È 04:24:49²Ä9926½g¦^À³
¦n¤[¨S¤W¨Ó¤F¡A¨S·Q¨ìªÑ»ùºCºC¦^¨ìÀ³¦³»ù­Èªº®É«á¡A¬°¤F¨p¶Ò¥i¥H³o¼Ë§n¡A§Ú¬O¤ä«ù¤pÃC¤jªº¡A¥u­n¡§À´ºÊ«ùªÑ¡¨¨S¦³²§±`¡A³o¦Xªkªº¶Ò¸ê§Úµ´¹ï¤ä«ù¡A§Ú¥ý©Ó»{°£¤F¨p¶Ò¥~¡A¨C¦¸ªº²{ª÷¼W¸ê§Ú³£¦³°Ñ»P¡A¦Ó¨C¦¸§Ú¤]½æ´X±i¦ÑªÑÁÈÂI¹s¥Î¿ú¡A¦n¯ºªº¬O¨C¦¸¼W¸êú´Ú«áªÑ»ù³£·|¤U±þ¶^¯}¼W¸ê»ù¡A§Ú¬O¤£¬O¤]¬O¥û¤â¤§¤@¡A§Ú¹ê¦b«Ü³Y²§¡§¤½¥q¸Û«H¡¨³o¦Ñ®C¥i¥H±qÃĵح·«BÄÆ·nªº®É«á¤@¦Aªº....¡A¥u¯à»¡Besremi³oÃĪº«e¡]¿ú¡^´º¤Ó°g¤H¤F
·|­û:¥ý¶i10000164µoªí®É¶¡:2021/12/28 ¤U¤È 03:20:20²Ä9925½g¦^À³
¥»¤H¦b¦¹±j½Õ¤@¤U¡A¹ïÃĵØÃĪº«á¶Õªø¦h¬Ýªk¤£ÅÜ¡A¦ý±j¯P¤Ï¹ï¨p¶Ò®×¡A¤½¥q¯Ê¿ú¥i¦V­ì©lªÑªF¥þÅé¼W¸ê¡A

­Y¤£Ãº´Úªº³¡¥÷¦A¥Ñ¸³¨Æªø¬¢¯S©w¤H¤h¡AÃĵØÃij̤֭n°µ¨ìÁ×¶û¡A¨p¶Ò®×¤@¦Ó¦A¤T¦h¤Ö¦¸¤F¡H§Ö¯}°O¿ý¤F§a

§Ú­n¦^À³¥»¸ÜÃD
·|­û:
§@ªÌ:
¬ÛÃöªÑ²¼¤½¥q¦WºÙ:ÃĵØÂåÃÄ
¤º®e:
½Ð¥ýµn¤J­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹
°Q½×°Ï¬ÛÃö³W©w¡G
1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«ØÄ³¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
4.¬°Á×§K®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C

¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178 ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѬÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!